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PREFACE 
This thesis envisioned the development of novel strategies for improving the 
effectiveness of allergen-specific immunotherapy (SIT). The increased prevalence of 
allergic disorders among the population in industrialized countries has encouraged 
scientists to investigate the basic mechanisms of allergy and has led to a re-evaluation of 
existing treatments.  
Almost hundred years have past since Freeman and Noon first described SIT. They 
subcutaneously injected hay fever allergic patients with increasing amounts of grass pollen 
extract. These incremental regime, which was necessary to minimize the risk of allergic 
reactions, still constitutes the basic principle of the current treatment, typically involving 
numerous injections over years.  
Although SIT is the only curative treatment with long-lasting effect and the potential to 
stop progression of the disease, less than 5 % of allergic patients undergo SIT. Over the last 
decades, several means to improve SIT safety and efficacy and, therefore, patient 
compliance have been investigated. My work focussed on three different approaches to 
improve the existing therapy: (i) the route of allergen administration, (ii) the use of 
modified recombinant allergen molecules, and (iii) the use of a polymer-based allergen 
delivery system with adjuvant potential. 
The use of a more efficient route of antigen administration such as the intranodal route 
could help to reduce the number of injections required for SIT. Moreover, intranodal 
injections require lower allergen doses to induce strong immune responses, reducing the 
risk of allergic reactions. The injection in subcutaneous lymph nodes is technically feasible 
and has already been performed in several clinical trials. The only additional requirement 
to standard SIT is ultrasound guidance. 
Modified recombinant allergens targeted to the MHC-II antigen presentation pathway 
via a truncated invariant chain sequence fused to the allergen, increases their 
immunogenicity and reduces human basophil degranulation as compared to the wild type 
recombinant allergen. Such allergens increase the efficacy without increasing the risk of 
allergic reactions. 
The combination of more immunogenic allergens with the more efficient intranodal 
route represents a promising tool to improve SIT and is planned to be tested soon in a phase 
II clinical trial. 
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Particulate delivery systems such as those made of poly(lactide-co-glycolide) (PLGA) 
show great potential for SIT, although their application to the clinics would still require 
further research. The capacity of PLGA to deliver antigens over prolonged periods of time 
could mimic the repeated booster injections of SIT. In addition to the depot effect, smaller 
PLGA particles (smaller than 10 µm) can be taken up by antigen presenting cells and 
thereby deliver allergens directly to lymphoid tissues. Furthermore, the co-encapsulation of 
other adjuvants can enhance and modulate immune responses.  
This thesis shows that the administration of allergens directly into secondary lymphoid 
organs, the use of modified recombinant allergens as well as the use of polymeric 
biodegradable microparticles for delivery of allergens, are all promising approaches to 
improve the current SIT treatment.  
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SUMMARY 
Nowadays, type I hypersensitivity reactions affect 20-30 % of the population in 
developed countries. Such reactions are associated with T helper 2 (Th2) cells and are 
mediated by IgE antibodies against substances, so called allergens, otherwise innocuous to 
the immune system. Pharmacotherapy is the most used treatment among allergic patients 
but it only ameliorates the symptoms without treating the cause of the disease. The only 
curative treatment for allergy patients that has a long lasting effect and that can stop 
progression of disease is allergen-specific immunotherapy (SIT). However, only 3-4 % of 
patients undergo SIT mainly because of three reasons: (1) the long duration of the 
treatment, which usually involves 30-80 subcutaneous injections over a time period of 3-5 
years, (2) the risk of allergic reactions, and (3) its high associated cost. Improving SIT by 
lowering the risk of adverse reactions and the number of injections would represent a 
significant advantage in terms of patient compliance and would also have socio-economical 
implications. 
Over the last decades efforts to improve SIT have focussed on optimizing the allergen 
molecules, their galenics including particulate delivery systems, such as virus like particles 
or poly(lactide-co-glycolide), the adjuvants, and more convenient routes of administration, 
i.e. oral and sublingual allergen administration. 
My PhD aimed at developing novel therapeutic strategies for SIT. In the first approach 
we tried to improve SIT by direct intralymphatic allergen administration (Chapter 2), in 
the second approach we used modified recombinant allergens (Chapter 3) and in the third 
approach we used polymeric biodegradable microparticles as an allergen delivery system 
(Chapter 4). 
In the first chapter of this thesis we investigated an alternative route for allergen 
administration. The geographical concept of immune reactivity postulates that for an 
immune response to occur antigens need to reach secondary lymphoid organs. Therefore, 
we proposed the direct administration of allergens into lymph nodes to stimulate the 
immune system more efficiently. In fact, we showed that intralymphatic injections induce 
stronger immune responses than the current used subcutaneous injections even with lower 
allergen doses. Additionally, only intranodal injections induced the Th1-associated 
antibody subclass IgG2a. Hence, by using the intranodal route of administration SIT can be 
shortened and the allergen dose lowered, which reduces the risk of allergic side effects. 
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The second project of this thesis tested the potential of targeting the MHC-II 
presentation pathway for allergy vaccines. The recently developed modular antigen 
transporter (MAT) allergens have a sequence derived from the Tat protein of HIV-1 for 
intracellular translocation and the first 110 amino acids from the human invariant chain 
targeting allergens to the MHC class II presentation pathway. We used the major cat 
allergen Fel d 1 as a model allergen and found increased immunogenicity with long-lasting 
Th1 associated antibodies and cytokines after three intralymphatic injections in mice 
immunized with MAT-Fel d 1 allergen compared to the normal recombinant allergen or the 
cat fur extract. Correspondingly, in a therapeutic model, mice desensitized with the 
modified allergens were better protected against anaphylaxis after a challenge with a high 
dose of the cat fur extract. MAT allergens increased the presentation efficiency without the 
need of increasing the allergen dose which would provoke adverse allergic reactions. 
Moreover, these modified allergens reduced basophil degranulation of cat allergic patients. 
This hypoallergenicity of the MAT-Fel d 1 allergen seemed to be explained by both its 
reduced IgE binding capacity and by the rapid internalization of the molecule due to the Tat 
sequence. 
In the third project, we studied the adjuvant capacity of poly (lactide-co-glycolide) 
(PLGA) microparticles. We encapsulated the major bee venom allergen, phospholipase A2 
(PLA2) as a model allergen, together with an immunomodulator, i.e. unmethylated CpG 
oligodeoxinucleotide, which is a known Th1 response inducer. PLGA are biocompatible 
and biodegradable polymers that are approved for use in humans. Moreover, they are 
attractive candidates for allergy vaccines because they release the encapsulated proteins 
over prolonged periods of time and would thereby reduce the need of numerous booster 
injections. In addition, entrapped allergen is less accessible for binding IgE on the surface 
of mast cells and basophils, reducing the risk of allergic reactions and anaphylaxis. In this 
study, we found that microparticles in combination with CpG were strongly immunogenic 
after two injections and were able to shift immune responses towards a Th1 type. The 
encapsulation of CpG proved to enhance immunogenicity as compared to admixed CpG. 
Additionally, co-encapsulation of protamine, used to stabilize CpG, further increased 
immunogenicity. The strong Th1 responses correlated with enhanced protection against 
anaphylaxis in bee venom allergic mice. These results indicate the potential of such 
formulations for use in SIT. 
Over the past years, PLGA formulations with surface modifications have been 
described for delivery of antigens or adjuvants. We prepared an additional PLGA 
  
   
9
formulation with encapsulated PLA2 and with protamine as a coating agent for adsorption 
of CpG to the microparticle surface. The immunogenicity of such coated particles with 
admixed CpG was similar to co-encapsulated CpG and protamine. However, in the absence 
of CpG, this formulation, unlike the uncoated particles, was able to induce a strong immune 
response. These results prompted us to study the effects of protamine-coated microparticles 
in different experimental settings and became an extra project of this thesis (Chapter 5). 
Interestingly, we always found increased T- and B-cell responses in vivo when protamine-
coated particles were used as well as enhanced particle uptake and antigen presentation in 
vitro. Protamines are small arginine-rich proteins that share great similarity with sequences 
from certain viral proteins such as Tat from HIV-1 and VP22 from herpes simplex virus. 
These sequences have a known translocation activity, which was also reported for 
protamine in 2005 by two independent groups. We therefore hypothesized that protamine 
could have a similar translocation activity on our coated microparticles. In fact, protamine-
coated microparticles containing plasmid coding for green-fluorescence protein were able 
to transfect the non-phagocytic HEK cell line. Additional research is needed to characterize 
such protamine-coated particles in order to develop further a new technology combining 
the advantages of microparticles for prolonged antigen release and protamine for 
facilitating cell penetration of the delivery system. The potential applications of such 
intracellular delivery system technology may span the areas of vaccine development, 
cancer immunotherapy, and gene/protein delivery. 
In conclusion, the novel SIT approaches presented in this work could represent an 
alternative to the current SIT treatment with reduced number of injections and lower risk of 
adverse events. In particular, the project with MAT allergens served to set up the basis for 
further clinical research in which a phase II clinical trial is planned in the near future. 
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ZUSAMMENFASSUNG 
Heute sind rund 20-30% der Bevölkerung industrialisierter Länder von Sofort-Typ 
Allergien betroffen. Diese Form der Hypersensitivitätsreaktionen entsteht dann, wenn das 
Immunsystem gegen ansonsten harmlose Substanzen mit der Bildung von T2-Helferzellen 
(Th2) reagiert, wodurch es zur Bildung von Antikörpern der Klasse IgE kommt. 
Die einzige kausale Therapie, die einen lang anhaltenden Effekt erzielen und das 
Fortschreiten der Krankheit aufhalten kann, ist die Allergen-spezifische-Immuntherapie 
(SIT). Dennoch unterziehen sich nur 3-4 % der Patienten dieser Therapie, was 
hauptsächlich auf die folgenden 3 Gründe zurückzuführen ist: (1) die lange Dauer der 
Behandlung, sie benötigt normalerweise 30-80 subkutane Injektionen über einen Zeitraum 
von 3-5 Jahren, (2) das Risiko allergischer Reaktionen und (3) die mit der Behandlung 
verbundenen hohen Kosten. Eine Verbesserung der SIT durch Verminderung der 
Nebenwirkungen und der Anzahl nötiger Injektionen würde zu einem enormen Vorteil 
bezüglich der Patienten Compliance führen und hätte auch sozioökonomische Vorteile. 
Um die SIT zu verbessern wurde in den letzten Jahrzehnten der Fokus vor allem auf 
eine Optimierung von Allergenmolekülen und ihrer Galenik mitsamt partikelartiger 
Trägersysteme gelegt, wie beispielsweise virus-ähnliche oder Poly(lactide-co-glycolide) 
Partikel, sowie auf eine Optimierung von Adjuvantien und geeigneteren 
Verabreichungsmethoden, z.B. sublingual oder oral. 
Meine Doktorarbeit hatte das Ziel neue therapeutische Strategien für die SIT zu 
entwickeln. In einem ersten Ansatz versuchten wir die SIT durch intralymphatische 
Verabreichung der Allergene zu verbessern (Kapitel 2), in einem zweiten Ansatz 
verwendeten wir modifizierte rekombinante Allergene (Kapitel 3) und in einem dritten 
Ansatz verwendeten wir polymere, biologisch abbaubare Mikropartikel  als 
Allergenträgersystem (Kapitel 4). 
Im ersten Kapitel dieser Doktorarbeit untersuchten wir alternative Wege der 
Allergenverabreichung. Antigene müssen die sekundären Lymphorgane erreichen, damit 
eine Immunreaktion ausgelöst wird. Deswegen versuchten wir durch direkte Verabreichung 
der Allergene in die Lymphknoten das Immunsystem effektiver zu stimulieren. Wir 
konnten tatsächlich zeigen, dass intralymphatische Injektionen stärkere Immunantworten 
auslösen als die klassischerweise verwendeten subkutanen Injektionen, selbst bei 
niedrigerer Dosierung der Allergene. 
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Ausserdem löste nur die Injektion in die Lymphknoten die Produktion von IgG2a 
Antikörpern aus, welche Th1-abhängig sind. Demzufolge kann die Dauer der SIT durch 
direkte Injektion der Allergene in die Lymphknoten verkürzt und gleichzeitig die Dosis der 
Allergene erniedrigt werden, wodurch das Risiko von Nebenwirkungen verringert wird.  
Im zweiten Projekt dieser Doktorarbeit versuchten wir die zur SIT verwendeten 
Allergenmoleküle so zu modifizieren, dass sie verstärkt auf MHC Molekülen der Klasse II 
präsentiert werden. Die vor kurzem entwickelten „modularen Antigentransporter“ (MAT) 
Allergene tragen eine Sequenz, die sich vom Tat Protein des HIV-1 ableitet, um so die 
intrazelluläre Translokation zu steuern. Weiterhin enthalten sie die ersten 110 Aminosäuren 
der menschlichen invarianten Kette, die das Allergen in den MHC-II Signalweg leitet.  
Als Allergiemodell verwendeten wir das Hauptallergen aus Katzenhaar, Fel d 1. 
Verglichen mit dem normalen rekombinanten Allergen oder Katzenhaarextrakt zeigte die 
Injektion von MAT- Fel d 1 eine erhöhte Immunogenität in Mäusen. 
Dementsprechend konnten wir auch Mäuse, welche zuvor mit Katzenhaarextrakt 
sensibilisiert wurden, mit MAT-Fel d 1 effizienter desensibilisieren als mit nicht 
modifiziertem Fel d 1 oder mit Katzenhaarextrakt. Nur die mit MAT-Fel d 1 
desensibilisierten Mäuse waren bei einer Provokation mit dem Katzenhaarextrakt gegen 
einen anaphylaktischen Schock geschützt. MAT Allergene erhöhten die 
Präsentationseffizienz ohne eine erhöhte Allergendosis zu benötigen, welche allergische 
Nebenwirkungen hervorrufen würde. Zudem reduzierten diese modifizierten Allergene die 
Degranulation von basophilen Granulozyten aus Patienten mit Katzenallergie. Diese 
hypoallergene Wirkung des MAT-Fel d 1 Allergenmoleküls schien durch seine reduzierte 
IgE Bindungskapazität und die rasche Internalisierung des Moleküls aufgrund seiner Tat 
Sequenz verursacht zu werden. 
Das dritte Projekt untersuchte die adjuvanten Eigenschaften von Poly(lactide-co-
glycolide) (PLGA) Mikropartikeln. Als Modellallergen vekapselten wir das Hauptallergen 
des Bienengifts, Phospholipase A2 (PLA2), zusammen mit nicht methylierten CpG-
Oligodeoxinukleotiden. Solche CpG-Nukleotide sind Immunmodulatoren, die für die 
Induktion von Th1-Reaktionen bekannt sind. PLGA sind biologisch kompatible und 
abbaubare Polymere, die für eine Verwendung im Menschen zugelassen sind. Zudem 
erscheint die Verwendung von PLGA für die SIT interessant, da PLGA die verkapselten 
Allergene über einen längeren Zeitraum hinweg freisetzen, wodurch möglicherweise die 
Anzahl der benötigten Allergeninjektionen reduziert werden könnte. Weiterhin sind 
verkapselte Allergene schlechter zugänglich für die Bindung an IgE, das auf der Oberfläche 
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von Mastzellen und basophilen Granulozyten gebunden ist, wodurch das Risiko von 
allergischen Reaktionen, inklusive der Anaphylaxie, reduziert wird. In dieser Studie zeigten 
wir, dass mit CpG kombinierte Mikropartikel nach zwei Injektionen bereits stark 
immunogen wirkten und die Immunreaktion in Richtung Th1 verschoben. Verglichen mit 
zugemischtem CpG erhöhte die Verkapslung von CpG die Immunogenität. Durch die 
zusätzliche Verkapslung von Protamin, das zur Stabilisierung von CpG dient, wurde die 
Immunogenität noch weiter verstärkt. In Mäusen mit Bienengiftallergie wurde eine 
Korrelation zwischen der starken Th1-Antwort und einem erhöhtem Schutz vor einer 
Anaphylaxie nachgewiesen. Diese Ergebnisse weisen auf das Potential solcher 
Formulierungen für den Einsatz in SIT hin. 
In den letzten Jahren wurden PLGA Formulierungen mit Oberflächenmodifikationen 
für den Transport von Antigenen oder Adjuvantien beschrieben. Wir stellten eine weitere 
PLGA Formulierung mit verkapseltem PLA2 her, die Protamin als beschichtende Substanz 
für die Adsorption von CpG an die Mikropartikeloberfläche enthielt. Die Immunogenität 
dieser beschichteten Partikel mit zugesetztem CpG war vergleichbar mit der von co-
verkapseltem CpG und Protamin. Im Gegensatz zu nicht beschichteten Partikeln konnte 
diese Formulierung jedoch auch in Abwesenheit von CpG eine starke Immunantwort 
induzieren. Diese Ergebnisse regten uns dazu an, die Effekte von protamin-beschichteten 
Mikropartikeln in verschiedenen experimentellen Fragestellungen zu untersuchen. Dadurch 
entstand ein zusätzliches Projekt in dieser Arbeit (Kapitel 5). Interessanterweise 
detektierten wir bei der Verwendung von protamin-beschichteten Partikeln immer erhöhte 
T- und B-Zellantworten in vivo und eine erhöhte Partikelaufnahme und 
Antigenpräsentation in vitro. Protamine sind kleine argininreiche Proteine, die eine grosse 
Ähnlichkeit mit Sequenzen bestimmter viraler Proteine wie Tat von HIV-1 und VP22 von 
Herpes Simplex Virus aufweisen. Diese Sequenzen besitzen eine bekannte 
Translokationsaktivität, die 2005 von zwei unabhängigen Gruppen auch für Protamin 
berichtet wurde. Wir stellten daher die Hypothese auf, dass Protamin auf unsere 
beschichteten Mikropartikel eine ähnliche Translokationsaktivität ausübt. Tatsächlich 
konnte eine nicht phagozytierende HEK Zelllinie mit protamin-beschichteten 
Mikropartikeln, die ein für das grün fluoreszierende Protein codierendes Plasmid 
enthielten, transfiziert werden. Die Anwendung einer solchen Technologie zum 
intrazellulären Transport wäre in der Entwicklung von Vakzinen, in der 
Krebsimmuntherapie und bei Gen- bzw. Protein-Transporten denkbar.  
  
   
13
Schlussendlich könnten die in dieser Arbeit vorgestellten neuen SIT Ansätze, die mit 
einer reduzierten Anzahl Injektionen und einem geringeren Risiko von Nebenwirkungen 
verbunden sind, eine Alternative zur aktuellen SIT Behandlung darstellen. Das Projekt mit 
MAT Allergenen diente bereits dazu, eine Grundlage für weitere klinische Forschungen zu 
schaffen. Zur Zeit findet eine klinische Studie der Phase I/IIa statt.  
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INTRODUCTION 
 
The term allergy was introduced more than a hundred years ago, and usually refers to 
immediate type hypersensitivity reactions according to the classification of Coombes and 
Gell in 1963, which today are known to be IgE mediated. Over the last 20 years, the 
prevalence of allergic rhinitis and rhino-conjunctivitis in industrialized countries has 
doubled (Durham et al., 1999b; Schoenwetter et al., 2004). The cumulative prevalence rate 
varies both within and between different countries, with studies indicating a 20% rate in the 
US and an average 23% prevalence in a population-based survey in Belgium, France, 
Germany, Italy, Spain and the UK (Bauchau and Durham, 2004).  
Several genetic and non-genetic factors have been identified to play a role in the 
development of allergies. Among the genes described to be involved in allergy 
susceptibility are those on chromosome 2 encoding for CD28, and CTLA-4, as well as 
those on chromosome 5 encoding for IL-3, IL-4, IL-5, IL-9, IL-13, GM-CSF and 
leukotriene C4 synthase (Steinke et al., 2008). On the other hand, environmental factors 
such as endotoxin exposure, air pollution and tobacco smoke have also been described to 
influence the onset of allergic diseases (Thomson, 2007). Likewise, the route of exposure, 
the dose of the allergen and some of its structural characteristics, e.g. enzymatic activity 
(Sokol et al., 2008), are also important factors for allergy development (Valenta and Kraft, 
2004). 
The pathophysiology of a type I hypersensitivity reaction (Fig. 1) begins when an 
allergen that enters the body is taken up by an antigen presenting cell, processed and 
presented to naïve CD4 T helper (Th) cells that differentiate into Th2 cells and secrete 
cytokines such as interleukin-4 (IL-4) and IL-13. IL-4 promotes immunoglobulin class 
switching in B cells to generate IgE antibodies, which are secreted and bind to their high 
affinity receptor FcεRI that is expressed on the surface of mast cells and basophils. IL-13 
also up-regulates IgE synthesis and induces the expression of adhesion molecules and 
chemokines important in airway inflammation (Wills-Karp, 2004). A second exposure to 
the allergen then leads to cross-linking of the surface bound IgE antibodies and their FcεRI 
receptors, which triggers the degranulation of mast cells and basophils releasing mediators 
such as histamine, leukotriens and prostaglandins. The released mediators cause 
vasodilatation, mucus secretion, smooth muscle contraction, and can manifest clinically as 
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allergic rhinitis, asthma, conjunctivitis, and eczema. Massive basophile degranulation 
manifests as systemic anaphylaxis (Akdis and Blaser, 2000). 
 
Figure 1. Pathophysiology of an allergic reaction (Goldsby, 2003). 
 
Currently, the only curative treatment of allergy is immune modulation through 
allergen-specific immunotherapy (SIT). SIT modifies the progression of allergy, and it may 
also prevent the progression to asthma in patients with allergic rhinitis (Bousquet et al., 
1998a; Frankland and Augustin, 1954; Malling, 2004; Wheeler and Woroniecki, 2004). 
Long-term effectiveness, with persisting relief of symptoms after cessation of treatment, 
has been demonstrated (Durham et al., 1999b), and SIT is therefore recommended as a 
first-line therapy for allergies (Bousquet et al., 1998b). However, only a few percent of 
allergy patients choose to undergo SIT, mainly because the treatment is very time 
consuming, as it requires 30-70 allergen injections over 3-5 years, and because the allergen 
injections frequently cause allergic side effects (Casale, 2004).  
During SIT, gradually increasing allergen doses are subcutaneously administered until a 
maintenance dose is reached, and then treatment continues for up to five years. Such 
lengthy treatment, often requiring as much as 80 allergen injections and frequently causes 
allergic adverse events. This is why the administered allergen doses must be kept relatively 
low, which favors Th2 immune responses (Ewbank et al., 2003; Fratil et al., 2006; 
Haugaard et al., 1993; Incorvaia et al., 2006; Von Garnier et al., 2002).  
Although progress has been made in the understanding of the immunological 
mechanism of SIT, the overall risk/benefit ratio of immunotherapy has not changed over 
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the last 30 years (Casale, 2004). This may be due to variations in clinical practice, errors in 
dosing, labeling and patient identification, the absence of standardized extracts for many 
important allergens or the administration of injections to inappropriate candidates, 
especially patients with poorly controlled asthma (Bousquet et al., 1998a; Casale, 2004; 
Passalacqua et al., 2004). Moreover, surveys of healthcare professionals involved in allergy 
treatment have confirmed that avoidable errors in patient and allergen identification and 
lack of adequate supervision following immunotherapy injections are largely responsible 
for treatment-associated fatalities first highlighted by a British report in 1986 (Medicines, 
1986). In the US, between 1990 and 2001, a total of 20 deaths were reported, 19 due to 
immunotherapy and one as a result of skin prick testing (Nelson, 2005). Fortunately, a 
number of recent developments suggest improvements in both the safety and the efficacy of 
immunotherapy. These improvements include the use of sublingual immunotherapy (SLIT) 
(Gidaro et al., 2005; Passalacqua et al., 2004), administration of synthetic peptides (Fellrath 
et al., 2003; Kay and Larche, 2004), recombinant and engineered allergens (Johansen et al., 
2005c; Kussebi et al., 2005; Valenta and Kraft, 2001) and the use of novel adjuvants 
(Degen et al., 2003; Johansen et al., 2005b). Other new developments include the use of 
“rush” or “ultra-rush” immunotherapy, by which the primary period of reaching the 
maintenance dose is shortened. Finally, the recently introduced anti-IgE antibody 
omalizumab (Rolinck-Werninghaus et al., 2004) (Bousquet et al., 2005; Casale et al., 2006) 
is presently being used in combination with conventional immunotherapy. Some of these 
new therapeutic options are reviewed in the context of existing practice.  
 
A SHORT HISTORY OF IMMUNOTHERAPY 
 
In 1819, the London physician John Bostock first described hay fever as a disease that 
affected the upper respiratory tract in hay-working farmers who showed allergic symptoms 
such as rhinitis, flushing, and increased temperature (Jackson, 2001). In 1869, Dr. Charles 
Blakely investigated his own hay fever and performed the first skin test by applying pollen 
through a small break in his skin (Jackson, 2001). In 1890, he noticed that administering 
grass pollen to the eyes of patients with hay fever symptoms, today known as the 
conjunctival provocation test, triggered allergy-like reactions. This was the first 
demonstration that exposure to pollen was the most probable cause of hay fever. In 1902, 
Drs. Charles Richet and Paul Portier introduced the word anaphylaxis when in the course of 
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other immunization research they discovered this life-threatening response to medications 
and protein substances (Jackson, 2001). Anaphylactic shock occurs within minutes after 
allergen exposure, causing symptoms such as swelling of body tissues, vomiting, cramps, 
sudden drop in blood pressure or even a loss of consciousness. It often occurs in people 
who are highly sensitive to penicillin, stinging insects, shellfish, and nuts and it must be 
treated as a medical emergency. Four years later, in 1906, the Austrian pediatrician 
Clemens von Pirquet first used the word allergy to describe the peculiar non-disease related 
symptoms developed by some diphtheria patients in response to treatment with horse serum 
antitoxin (Jackson, 2001). The word comes from the Greek word “allo”, meaning, “change 
in the original state”. Indeed, an allergic reaction is the result of the body's change when it 
adversely responds to a harmless substance. 
Between 1911 and 1914, the work of Leonard Noon and John Freeman at Saint Mary's 
tuberculosis hospital in London helped to establish the basis for immunotherapy (Freeman, 
1911; Freeman, 1914; Noon, 1911). They treated hay fever patients with subcutaneous 
injections of increasing amounts of aqueous grass pollen extract, starting with very low 
doses in order to minimize the risk of potentially life-threatening anaphylactic reactions. 
The maximum dose was administered just before the start of the pollen season. 
Improvement of symptoms occurred in approximately 75% of the patients. Back then, at a 
time where IgE was not discovered, Noon and Freeman thought that the pollen-induced 
symptoms were caused by toxins in the pollen. Being inspired by their colleague Dr. 
Wright, who at that time was introducing typhoid vaccination in England, Noon and 
Freeman wanted to use pollen extracts to vaccinate against those toxins. The treatment 
regime introduced by Noon and Freeman has essentially remained unchanged over the last 
century. Subcutaneous injections of allergens has remains the preferred SIT method 
(Wheeler and Woroniecki, 2004).  
 
MECHANISMS OF ALLERGEN-SPECIFIC IMMUNOTHERAPY  
 
SIT has been shown to reduce both symptoms of allergy and the need for 
supplementary symptomatic medication. In controlled clinical trials, SIT improved the 
quality of life of treated individuals (Bousquet et al., 1998c; Jayasekera et al., 2007; Till et 
al., 2004). SIT increases tolerance to allergen challenge, and decreases immediate and late-
phase IgE-mediated allergic inflammation. These changes are associated with changes in 
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cellular and humoral responses to the allergen (Fig. 2). Following SIT, the ratio of Th1 to 
Th2 cytokines is increased (Bousquet et al., 1998b), and allergen-specific regulatory T cells 
are induced (Akdis and Blaser, 2000). The production of IL-10 by monocytes, 
macrophages, B cells and T cells is increased (Akdis et al., 2001; Robinson et al., 2004). 
The expression of transforming growth factor- β (TGF-β) is increased and, together with 
IL-10, TGF-β might contribute to regulatory T-cell function and immunoglobulin class 
switching to IgA, IgG1 and IgG4 (Jeannin et al., 1998; Levings et al., 2002; Nouri-Aria et 
al., 2004). These immunoglobulins compete with free- or surface bound-IgE for allergen 
binding (Durham and Till, 1998; Reisinger et al., 2005). This competition decreases 
allergen capture and presentation that is facilitated by IgE via its high-affinity (FcεRI) or 
low-affinity receptor (FcεRII) (van Neerven et al., 1999). In the late phase of an IgE 
mediated allergic reaction, eosinophils, neutrophils and basophils are recruited to the site of 
inflammation where they perpetuate the inflammatory response by releasing inflammatory 
mediators. Successful SIT has been shown to reduce the number of mast cells and their 
ability to release mediators (Durham et al., 1999a). Also the recruitment of eosinophils and 
neutrophils to sites of allergen exposure is reduced (Varney et al., 1993). 
 
 
 
Figure 2. Mechanisms of SIT (Larche et al., 2006). The parameters that increase after SIT are illustrated in 
blue and the ones that decrease in red. 
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NOVEL STRATEGIES IN IMMUNOTHERAPY 
 
The major disadvantages of current allergen SIT are its long duration, the high number 
of injections required and the associated high costs. SIT is also associated with a significant 
risk of severe allergic reactions. It is therefore of great interest to improve SIT by reducing 
the number of required injections, and to reduce the side effects by optimizing the allergen 
type, dose and route of administration. The advantages and disadvantages associated with 
the strategies used to improve SIT described in this text, are illustrated in Table 1. 
 
Routes of Administration 
 
An important issue in immunotherapy is the route of allergen administration. Interest in 
alternative routes increased sharply in response to a 1986 report from the British 
Committee for the Safety of Medicines showing 26 fatalities caused by subcutaneous 
immunotherapy (Medicines, 1986). Nasal administration has been shown to be effective 
(Barbey et al., 2004) but its use may be limited by local side-effects, i.e.nasal discharge, 
blocking and sneezing. In 1999, a Position Paper by a group of experts at the World Health 
Organization (WHO) concluded that in particular the sublingual route of allergen 
administration was a viable alternative to the subcutaneous route (Bousquet et al., 1999). 
More recently, we have suggested that injection of allergens directly into lymph nodes may 
represent a valuable alternative to conventional SIT (Johansen et al., 2005b; Johansen et al., 
2005c).  
 
(i) Subcutaneous immunotherapy 
Subcutaneous immunotherapy has been shown to be a highly effective treatment for 
seasonal allergic rhinitis. A systematic review by WHO experts concluded that 
immunotherapy was effective in the treatment of allergies to insect venoms and to inhalant 
allergens, such as pollen, dust mite, cat hair, and mould (Bousquet et al., 1998a). SIT had a 
beneficial effect on bronchial symptoms and decreased the need for asthma medication in 
patients with allergic asthma due to pollen. Subcutaneous immunotherapy appears to be 
more effective in patients with single rather than multiple allergies and more effective in 
the treatment of pollen-induced seasonal rhino-conjunctivitis than perennial allergy. Long-
term exposure to perennial allergens such as dust mite and mould may cause permanent 
inflammatory changes to airway mucosa and even irreversible remodeling of lung tissue in 
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patients leading to chronic asthma. In patients with bronchial symptoms to cat allergens, 
subcutaneous immunotherapy resulted in improvement of symptoms and a reduction in the 
need for medication. After many years of debate, a landmark study, which revealed that 
subcutaneous immunotherapy against grass pollen allergy lead to clinical remission and 
persisting reduction in immunological reactivity, confirmed the long-term efficacy of SIT 
(Durham et al., 1999b). 
High efficacy of subcutaneous immunotherapy is observed in insect venom allergic 
patients. The efficacies are typically 80-95%, and such Hymenoptera-venom 
immunotherapy represents the only effective prophylactic treatment for insect sting-
induced anaphylaxis (Bousquet et al., 1998a; Casale, 2004; Golden, 2005). SIT is, 
therefore, recommended as the first line therapy for patients with a history of severe 
systemic allergic reactions to insect stings. After three to five years of immunotherapy most 
patients remain protected against subsequent stings, even if they remain skin test positive 
(Bousquet et al., 1998a). Only 25% of patients become skin-test negative after 3-5 years of 
insect venom SIT and after 7-10 years 60–70% of patients become skin test negative 
(Golden, 2005). If patients become skin test negative, it is considered safe to discontinue 
venom subcutaneous immunotherapy (Bousquet et al., 1998a). 
 
(ii) Sublingual immunotherapy 
In sublingual immunotherapy (SLIT), the allergen is given as tablets or as drops that are 
kept under the tongue for a few minutes (Gidaro et al., 2005; Passalacqua et al., 2004). 
Although a WHO Position Paper in 1998 stated that only four studies had by then 
demonstrated the clinical effectiveness of sublingual-swallow immunotherapy (Bousquet et 
al., 1998a; Malling et al., 1998), its efficacy has been assessed in a number of studies in 
recent years. A further advantage of SLIT is that it enhances compliance, likely due to both 
the low rate of side-effects (Nelson, 2005) and the needle-free administration at home. 
A meta-analysis of 22 randomised double-blind, placebo-controlled trials involving 979 
patients with allergic rhinitis caused by house dust mite, grass pollen, Parietaria, olive and 
ragweed allergens (Wilson et al., 2005) revealed significant reductions in both rhinitis 
symptoms and medication requirements following SLIT. Moreover, the direct comparison 
of subcutaneous SIT and SLIT showed similar improvements both in symptoms and 
medication requirements for the two routes of administration (Wilson et al., 2005). 
However, it should be noted that the allergen doses used in recent SLIT studies were from 
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3–500 times higher than those used in subcutaneous immunotherapy (Gidaro et al., 2005; 
Malling, 2004; Wilson et al., 2005).  
SLIT has also been shown to reduce symptoms and use of β2-agonists and systemic 
steroids in patients with allergic asthma (Bousquet et al., 1999; Passalacqua et al., 2004; 
Purello-D'Ambrosio et al., 1999). Improvements in lung function, bronchial hyper-
reactivity and quality of life have also been noted (Bousquet et al., 1999; Lombardi et al., 
2001). At least one study indicated that the efficacy of SLIT in allergic asthma is dose 
dependent (Andre et al., 2003). Despite the limited data available to assess the long-lasting 
effect of SLIT in asthma, a recent study performed in 35 children treated for 4–5 years with 
SLIT indicated a significant improvement of asthma, as long as five years after 
discontinuation of treatment (Di Rienzo et al., 2003; Passalacqua et al., 2004).  
Current research to improve SLIT focuses on optimizing the allergen molecules and the 
adjuvants used. For instance, the intranasal administration of recombinant Bet v 1, the 
major birch pollen allergen, was shown to reduce systemic allergic immune responses and 
airway inflammation in birch pollen sensitized mice (Winkler et al., 2002). In the same 
way, oral administration of a T-cell epitope peptide from the major Japanese cedar, allergen 
Cry j 2, induced immunological tolerance in previously sensitized mice (Yoshitomi et al., 
2007). Chimeric allergens composed of the recombinant Bet v 1 allergen linked to two 
peptides derived from the major grass pollen allergens Phl p 1 and Phl p 5, induced 
mucosal tolerance when used prior to poly-sensitization and were suggested to prevent 
multi-sensitizations (Wild et al., 2007). Alternatively, the modification of allergens with 
mucoadhesives, e.g. maltodextrin, not only enhanced mucosal adhesion of the allergen, but 
also induced tolerance by reducing airway hyper-responsiveness, airway inflammation and 
IL-5 production in mice, which consequently increased the efficacy of SLIT 
(Razafindratsita et al., 2007). Furthermore, several studies have used adjuvants such as 
polymeric microparticles to increase the immunogenicity of encapsulated antigens for oral 
and intranasal administration in mice (O'Hagan, 1998; Roth-Walter et al., 2005; Vajdy and 
O'Hagan, 2001). In a recent study in mice, intranasal administration of an allergenic 
peptide encapsulated in PLGA microparticles prevented subsequent systemic allergic 
immune responses and airway inflammation to the whole allergen (Marazuela et al., 2008). 
Additionally, the use of microparticles containing timothy grass pollen extract for oral 
immunization in allergic patients has been shown to reduce effectively medication and 
symptoms scores (TePas et al., 2004).  
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(iii) Other routes of administration 
In mice, the immunogenicity of antigens administered directly into a subcutaneous 
lymph node (intranodal administration) has been shown to be superior to the conventional 
subcutaneous administration (Johansen et al., 2005a; Maloy et al., 2001). Such 
intralymphatic immunization triggers Th1-like immune responses with enhanced secretion 
of IgG2a antibodies and reduced IgE production. In contrast, subcutaneous immunization 
with allergens induces Th2-associated IgG1 and IgE antibodies and little IgG2a. Intranodal 
injections require lower allergen doses than subcutaneous administration. This also reduces 
the risk of allergic reactions in SIT (Martínez Gómez et al, paper submitted). The first 
phase I/IIa clinical trials using the intranodal route of administration to desensitize allergic 
patients has revealed promising results. The results from a double-blinded phase I/II trial 
on grass and tree pollen allergic patients suggested that the efficacy of eight weeks with 
intranodal immunotherapy was comparable to three years of immunotherapy with 
conventional subcutaneous injections (Senti et al, paper submitted). Hence, intranodal 
immunotherapy may be a promising alternative to subcutaneous SIT not only in terms of 
efficacy and safety, but also in regard to compliance, since the treatment time can be 
strongly reduced. 
Allergens 
 
In the US the original type of immunotherapeutic aqueous allergen extracts, which 
contain a mixture of molecules from pollen, mould, dust mite or other allergenic 
substances, are still widely used, despite the risk of allergic side effects upon 
administration. In Europe, purified and modified allergens and adjuvants forming a slow 
release depot are used to reduce this risk. To produce purified extracts, unwanted low 
molecular weight material is removed, as most true allergens have a molecular weight > 10 
kDa (Wheeler and Woroniecki, 2004). 
One strategy to increase safety and tolerability of SIT is to inject the allergen in a form 
that is not recognized by IgE. In the 1970-80s allergens were chemically modified by using 
formaldehyde, glutaraldehyde, tyrosine, alginates to form so-called allergoids (Bousquet et 
al., 1998a; Degen et al., 2003; Patterson et al., 1977; Wheeler and Woroniecki, 2004). 
These methods not only reduced reactogenicity with IgE, but also improved antigen 
processing, Th1 cytokine secretion, and therapeutic efficacy (Bousquet et al., 1990; Gieni 
et al., 1996; Grammer et al., 1987). More recently, naked DNA vaccines expressing an 
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allergen have been utilized (Jilek et al., 2001; Jilek et al., 2004). Recombinant DNA 
technology has also facilitated the production of mutated allergens with low IgE-binding 
capacity (Ferreira et al., 1998; Kussebi et al., 2005; Schmid-Grendelmeier et al., 2003; 
Tresch et al., 2003; Valenta and Kraft, 2002; Westritschnig et al., 2004), allowing the use 
of higher therapeutic doses (Andre et al., 2003; Ewbank et al., 2003). For the same reason, 
short, synthetic peptide sequences corresponding to T-cell epitopes from the allergen which 
but do not bind IgE have been used for SIT (Alexander et al., 2002; Kay, 2004; von 
Garnier et al., 2000).  
 
(i) Recombinant allergens 
Advances in molecular biology have allowed the cloning of most common allergens 
and the investigation of their nature (Valenta and Kraft, 2002). This has allowed production 
of defined allergens, or recombinant molecules with improved immunological properties 
derived from the original allergens. The technology has opened new avenues in diagnostics 
and in immunotherapy (Chapman et al., 2000; Ferreira et al., 2002; Valenta and Kraft, 
2004; Valenta and Niederberger, 2007). 
Wild-type recombinant allergens mimic the immunological and structural properties of 
natural allergens. They can replace allergen extracts, offering the advantage that defined 
molecules in defined quantities and quality can be formulated as vaccines. Wild-type 
allergens have been used in animal models to induce blocking antibodies (de Weerd et al., 
2003; Swoboda et al., 2004) and tolerance (Hufnagl et al., 2003). Clinical efficacy has been 
demonstrated n a randomized, double-bind, placebo controlled trial using several 
recombinant grass pollen allergens for SIT. (Jutel et al., 2005). Alternatively, the covalent 
linking of several major allergens to form hybrid allergen molecules was found to increase 
the immunogenicity of the individual components and, hence, to induce higher levels of 
blocking antibodies in animals than vaccination with a mix of the allergens (Kussebi et al., 
2005; Linhart et al., 2005). Although the treatment with wild type-like allergens offers 
advantages with respect to pharmaceutical quality, standardization and dosage formulation 
of the vaccine, so far the duration of the treatment remains similar to SIT with allergen 
extracts.  
Recombinant technology has also paved the way for modified allergens or so-called 
bioengineered muteins (Bousquet et al., 1998a; Devos et al., 1995; Wheeler and 
Woroniecki, 2004). Muteins are modified allergen molecules that retain the ability to 
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stimulate Th1 responses but do not react with allergen-specific IgE antibodies (Bhalla et 
al., 2001; Swoboda et al., 2002). They are derived from allergenic proteins by replacing of 
one or more amino acids from their IgE antibody binding sites. For instance, by mapping 
sequential epitopes on the major shrimp allergen, tropomyosin (Pen a 1), a mutant with 
strongly reduced allergenicity but with potential therapeutic use was generated (Reese et 
al., 2005). We have developed and tested recombinant fusion proteins carrying additional 
immunological targeting sequences, such as the so-called Modular Antigen Transporter 
(MAT)-allergens (Fig. 3) (Crameri et al., 2007). These allergens enable the rapid 
translocation of the allergen into antigen-presenting cells (through a Tat sequence derived 
from the human immunodeficiency virus) and targeting to the MHC class-II presentation 
pathway (through a truncated human invariant chain, li). We showed that MAT-Fel d 1 
allergen increased therapeutic immunogenicity of Fel d 1 in mice, inducing high levels of 
IgG2a and IFN-γ, while reducing IL-4 secretion by allergen specific T cells. At the same 
time MAT-Fel d 1 showed reduced degranulation of human basophils as compared to wild-
type recombinant allergen, suggesting reduced binding of surface IgE (Martínez Gómez et 
al. paper submitted). 
Likewise, a novel Fcγ-Fel d 1 bifunctional fusion protein was shown to inhibit FcεRI-
mediated degranulation in a dose-dependent manner by direct cross-linking of anti-Fel d 1 
IgE bound FcεRI (IgE high affinity receptor) and FcγRIIb (receptor containing inhibitory 
motifs) on the surface human mast cells and basophils (Zhu et al., 2005, Zhang, 2007 
#1208). Immunization of Fel d 1-sensitized mice with Fcγ-Fel d 1 has been shown to block 
systemic allergic reactivity. The inhibition of histamine release from mast cells and 
basophils of cat allergic donors was associated with altered Syk and ERK signaling (Terada 
et al., 2006).  
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Figure 3. Proposed mechanism for an increased antigen presentation through the MHC-II presentation 
pathway. Modular antigen translocation (MAT) vaccines consist of a translocating peptide (green) converting 
extracellular to cytoplasmic proteins, a domain derived from the invariant chain Ii (blue) targeting the fusion 
protein to the endoplasmatic reticulum where assembly of MHC-II and Ii complexes occurs, and an allergen 
of interest fused C-terminally to Ii (red) (Crameri et al., 2007). 
 
The safety benefits of recombinant and engineered allergens remain to be fully 
determined, but early results with a genetically modified Bet v 1 allergen demonstrate its 
immunotherapeutic efficacy (Niederberger et al., 2004; Niederberger et al., 2007). 
However, the theoretical advantages of such molecules may be outweighed by high 
production costs and the pharmaceutical development of such molecules as pharmaceutical 
products. As  most allergies are caused by multiple allergens, e.g. hay fever and house dust 
mite allergy, a vaccine would have to consist of numerous different recombinant allergen 
molecules. In this respect, an alternative and easier non-recombinant method to reduce IgE-
binding capacity has been achieved by physical disruption of the secondary and tertiary 
structure of protein allergens by heat-denaturation (Koppelman et al., 2002; Magi et al., 
2004). The use of heat-denaturation is in line with the clinical observations that allergic 
individuals usually tolerate cooked food better than raw food (Sanchez-Monge et al., 2000). 
In mice, heat-denatured allergens showed a lower sensitization potential but enhanced 
IgG2a antibody- and Th1-inducing capacity, showing the potential of such allergens for use 
in SIT (Johansen et al., 2005c). 
 
(ii) Peptides 
The use of short immunodominant peptides derived from allergens have been shown to 
decrease the risk of anaphylaxis inherent to allergen-specific immunotherapy (von Garnier 
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et al., 2000). Therapeutic peptides typically contain T-cell epitopes that trigger T-cell 
immune responses, but lack IgE reactivity (Fellrath et al., 2003; Kay and Larche, 2004; 
Wheeler and Woroniecki, 2004). This approach was successfully applied with restricted 
sets of immunodominant peptides derived from Fel d 1, bee venom phospholipase A2 
(Api m 1) (Fellrath et al., 2003; Muller et al., 1998; Norman et al., 1996; Von Garnier et 
al., 2002; von Garnier et al., 2000), or Bet v 1 in mice (Bauer et al., 1997; Briner et al., 
1993; Oshiba et al., 1996). A mixture of three short peptides that stimulated T-cell clones 
from allergic and non-allergic study subjects were used in patients allergic to bee venom 
(Muller et al., 1998). These subjects subsequently tolerated an injection of Api m 1 
equivalent to one bee sting and some subjects were able to tolerate a bee sting. Similarly, in 
studies using the peptides derived from Fel d 1, efficacy was demonstrated, but the FDA 
put further trials on hold, as several hours after the peptide injection a T cell mediated  late 
phase asthma response was observed (Norman, 2004; Wheeler and Woroniecki, 2004). 
Intranasal administration of the immunodominant house dust mite allergen Der p 1 in 
primed mice reduced T-cell responses not only to the epitope, but also to the entire protein 
via so-called linked immunosuppression (Hoyne et al., 1993). However, though these 
studies were promising, contradicting data were also published. Spertini and co-workers 
showed that intranasal therapy with ovalbumin (OVA) but not with its major T-cell epitope 
led to T-cell activation and the induction of IL-10 secreting CD4 T-cells in the bronchial 
lymph nodes (Barbey et al., 2004). Subcutaneous immunization with the major T-cell 
epitope-containing peptide of the house-dust mite Der p 2 elicited a strong immune 
response rather than a state of tolerance (Wu et al., 2000). In a murine model of asthma, 
immunotherapy with OVA reduced airway eosinophilia and hyper-responsiveness, whereas 
immunotherapy with the immunodominant OVA peptide 323–339 enhanced them (Janssen 
et al., 1999). 
Although peptides that do not bind IgE might represent a good alternative to wild-type 
allergens, they do not strongly induce blocking IgG antibodies, and hence, they may not be 
appropriate for SIT. More research is required to define the epitopes and the sequences that 
on the one hand do not bind IgE and on the other hand induce T- and B-cell responses that 
lead to desensitization or tolerance. While mouse studies used inbred strains with defined 
MHC class II molecules, another obstacle to clinical use is the HLA variation within the 
human population.  
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Adjuvants 
 
Adjuvants are defined as a group of structurally heterogeneous compounds, used to 
evoke or increase immune responses to antigens (Gupta et al., 1993). Classical adjuvants 
include oil emulsions, saponins, aluminum or calcium salts, non-ionic block polymer 
surfactants, and derivatives of mycobacteria, lipopolysaccharides, and other bacterial or 
viral components (Marciani, 2003; O'Hagan and Valiante, 2003; Villinger, 2003). Although 
the structural requirements of effective adjuvants as well as the molecular and cellular 
mechanisms behind effective immune responses are not yet completely understood, they 
have been classified according to five recently proposed concepts of immunogenicity 
(Schijns, 2000): i) the geographical concept of immune reactivity; ii) the theory of depot 
effect; iii) the paradigm that adjuvants act as Signal 0 characterized by pathogen 
recognition through PAMPS (Janeway, 1989); iv) the role of Signal 2 molecules as natural 
adjuvants in the activation of naive T-helper cells; v) the hypothesis that immunity is 
activated by exogenous and eventually endogenous danger (Matzinger, 2002). 
The adjuvants used in SIT have typically been aluminum and calcium salts. Apart from 
causing local granuloma formation at the injection sites, these adjuvants have a good safety 
record (Gupta, 1998). Major disadvantages of aluminum hydroxide are the unpredictable 
efficacy of adsorption of certain allergens/allergen extracts and stability of the adsorbates, 
the possibility that allergens are altered in the course of the undefined adsorption process 
and the difficulties in assessing quality and quantity of allergens once they are adsorbed. 
Furthermore, they produce poor T-cell responses, triggering preferentially Th2 responses 
(including IgE antibodies) rather than the therapeutically more favorable Th1 responses. 
Therefore, an important part of the research to improve SIT now focuses on the use of 
alternative adjuvants that trigger innate immunity to counterbalance the Th2 immune 
responses (Vandenbulcke et al., 2006; Yang et al., 2006). 
 
(i) Toll-like receptor ligands 
The theory known as the hygiene hypothesis suggests that diminished exposure to early 
childhood infections and environmental bacterial components has resulted in a population 
that is predisposed to allergies and has, therefore, been suggested as an explanation for the 
rising prevalence of allergic disorders (Ponsonby and Kemp, 2008; Yazdanbakhsh et al., 
2002). A number of studies support an inverse association between early infectious 
exposures and the development of allergic diseases (Illi et al., 2001; Matricardi et al., 
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2002). Several microbial components, which are recognized by pattern-recognition 
receptors such as Toll-like receptors (TLRs) can directly activate immune cells (Akira et 
al., 2006; Kaisho and Akira, 2006). Thus, the reduced microbial stimulation of the TLRs in 
early life, which could lead to a weaker Th1 response and a stronger Th2 response to 
allergens plays a key role in the hygiene hypothesis to. It is believed that compounds that 
can control the over-expression of Th2 cytokine-secreting cells or skew the Th2-Th1 
balance towards the latter would be of clinical advantage for allergy vaccination (Chisholm 
et al., 2004; Gangloff and Guenounou, 2004). In this respect the use of TLR agonist as 
adjuvants has opened up new avenues for SIT (Akdis et al., 2003; Degen et al., 2003; 
Johansen et al., 2005b). 
Lipoproteins and lipoteichoic acid (LTA) from Gram-positive bacteria are recognized 
as a pathogen-associated potential threat by TLR2, which is localized on the surface of 
immune cells, especially DCs. The stimulation of the innate immune system by the 
synthetic lipopeptide LP40, which binds to TLR2 and signals through MyD88, induces  IL-
10, IL-12 and IFN-γ, and inhibits Th2 cells and IgE production in human PBMCs and also 
lung eosinophilia in several mice models (Cezmi A. Akdis, 2003). Another TLR2 agonist, 
the synthetic triacylated lipopeptide Pam3CSK4, was shown to attenuate OVA-induced 
asthma in mice. This attenuation of asthma was also associated with increased IL-12, IFN-γ 
and IL-10 production (Patel et al., 2005). Similarly, the Gram-positive bacteria, 
Lactobacillus plantarum, was shown to modulate allergen-specific responses both in vitro 
and in vivo after its co-administration with Der p 1. Increased Th1-associate cytokines, IL-
12 and IFN-γ, were observed as well as increased secretion of IgG2a antibodies, and 
reduced eosinophilia. Again the prevention of allergic responses was modulated by TLR2 
and MyD88 (Hisbergues et al., 2007). A different study showed that L. plantarum induced 
IL-10 gene expression in DCs and naïve CD4 T cells, and enhanced the efficacy of 
sublingual immunotherapy in a murine asthma model (Van Overtvelt et al., 2008). 
Several mycobacterial products have been found to activate TLR2 and TLR4 
(Heldwein and Fenton, 2002), and to induce strong IFN-γ responses (Walker et al., 2003). 
Pre-treatment of asthmatic mice with the heat-killed Mycobacterium vaccae conferred 
long-term antigen-specific protection from OVA-induced airway inflammation (Zuany-
Amorim et al., 2002). In humans a double-blind trial evaluated the potential of heat-killed 
M. vaccae in patients with atopic asthma (Camporota et al., 2003). Participants were given 
a bronchial allergen challenge before and after treatment and their early and late asthmatic 
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responses were monitored. However, despite reduction in the late asthmatic responses, the 
results were not significantly different from the placebo group.  
Lipopolysaccharide (LPS) is a cell-wall component of Gram-negative bacteria that 
binds to TLR4. The role of LPS and its receptor in allergies is well known (Williams et al., 
2005). It has been shown that both the amount and the time of the exposure to LPS 
determine the type of immune responses elicit following LPS administration. Inhalation of 
low levels of LPS triggered Th2 responses, whereas high LPS levels resulted in Th1 
responses (Eisenbarth et al., 2002). Exposure to LPS early in the sensitization process 
prevented the development of allergies. In contrast, later exposure aggravated the 
inflammatory reaction (Tulic et al., 2000). Monophosphoryl lipid A (MPL), a derivative 
from the LPS of Salmonella minnesota that maintains its pro-inflammatory properties but 
with a lower toxicity, has been shown to induce Th1-skewed immune responses (Wheeler 
et al., 2001). Several clinical trials have already evaluated the potential of using MPLs in 
humans (Drachenberg et al., 2001; Mothes et al., 2003). Four pre-seasonal injections of 
MPL-adjuvanted grass pollen allergoid successfully improved symptoms and medication 
scores. These effects were associated with high titers of allergen-specific IgG1 and IgG4 
antibodies, which could block allergen-dependent degranulation of basophils (Mothes et 
al., 2003). Despite positive initial results the FDA has stopped phase III trials  because of 
safety concerns (http://www.biospace.com/news_story.aspx?NewsEntityId=62636). 
Furthermore, two synthetic triacylated pseudo-dipeptides agonists of TLR4 have been 
described to induce human DC maturation and polarization of naïve T cells towards IFN-γ 
producing Th1 cells (Mascarell et al., 2007). However, only one of the molecules, OM-
294-BA-MP, was able to induce IL-10 gene expression and enhance tolerance after 
sublingual administration in mice with established asthma to OVA. 
The genetic material of microbes has an excellent immune stimulating capacity. Indeed, 
viral double- and single-stranded RNA is recognized by the endosomal receptors TLR3 and 
TLR7/8, respectively. A synthetic compound, R-848, also called resiquimod, from the 
imidazoquinoline family that binds to TLR7 and TLR8 in humans, was shown to shift the 
differentiation of allergen-specific human CD4 T cells in vitro from a dominant Th2-like 
response to a prevalent Th1-like response. This strong polarizing capacity was attributed to 
the effect of R-848 on cells from the innate immune system, such as macrophages, natural 
killer cells and DCs (Brugnolo et al., 2003). Similarly, a study in mice showed that a single 
intranasal injection of R-848 in OVA-sensitized mice effectively inhibited allergen-induced 
airway inflammation and hyper-reactivity by reduction of Th2 responses and increased 
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production of IL-12 and IFN-γ (Quarcoo et al., 2004). Polyinosinic:polycytidylic acid 
(PolyI:C) a synthetic double-stranded RNA agonist of TLR3 prevented and suppressed 
asthma in mice as a consequence of the additive effects of IL-10 and IL-12 (Sel et al., 
2007).  
TLR9 is another endosomal receptor that detects unmethylated CpG-rich sequences 
relatively common in the genomes of most bacteria and DNA-viruses. In humans, TLR9 is 
mainly expressed in B cells and plasmacytoid DCs, whereas in mice TLR9 is also 
expressed in monocytes and myeloid DCs (Iwasaki and Medzhitov, 2004). It has been 
shown that CpG oligodeoxinucleotides trigger direct B cell activation (Krieg et al., 1995) 
and that TLR9 can regulate isotype switching to IgG2a not only through activation via Th1 
cells (Krieg, 2006) but also by direct interaction with B cells (Jegerlehner et al., 2007). The 
immunomodulatory effect of CpG motifs can suppress IgE responses induced by both 
protein and plasmid DNA allergens (Peng et al., 2004), redirect the allergic Th2 responses 
towards Th1 responses and prevent the development of airway inflammation in mice both 
prophylactically and therapeutically (Banerjee et al., 2004; Jahn-Schmid et al., 1999; Jain 
et al., 2003). Furthermore, the conjugation of Amb a 1, a ragweed pollen major allergen, to 
CpG motifs led to reduced airway hyper-responsiveness in ragweed-sensitized mice. This 
effect was associated with increased IFN-γ and IgG2a levels (Santeliz et al., 2002). A 
recent study has shown that immunotherapy with CpG DNA conjugated with a T-cell 
peptide from the Japanese cedar pollen major allergen Cry j 2, was also useful in 
preventing and treating allergic conditions (Suzuki et al., 2007). 
These promising pre-clinical results have led to several clinical trials. The use of Amb a 
1 linked to CpG (AIC) to stimulate PBMCs of ragweed allergic patients induced Th1 
responses instead of the Th2 responses.. The treatment of ragweed allergic subjects with 
escalating doses of AIC was found to reduce ex vivo ragweed-specific Th2 responses (IL-5, 
CCL17, and CCL22), and a transient increase of IFN-γ, CXCL9, and IL-10 was observed 
(Simons et al., 2004). In two separate studies with six escalating doses of AIC, reduced 
nasal symptoms as compared to placebo treatment were observed (Creticos et al., 2006; 
Tulic et al., 2004). Moreover, the protective effect against ragweed-induced symptoms was 
still observed during the second ragweed season and no increase in serious adverse events 
was reported. However, the phase III studies have just recently been suspended, as they did 
not meet their end points (http://www.apmhealtheurope.com/depechesPublieesDepeches. 
php?annee=2007&mois=2&jour=27). 
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The risk of rapid degradation of CpG by nucleases together with the fact that TLR9 is 
an intracellular receptor has made the idea of its encapsulation in particulate systems such 
as liposomes (Joseph et al., 2002), VLPs (Storni et al., 2004) and PLGA (Hunter et al., 
2001; Martinez Gomez et al., 2007) especially attractive. Some of these systems have been 
evaluated in allergy vaccines and will be described in the next section. 
 
(ii) Particles  
Particles have been subject to intense investigation with regard to their adjuvant 
potential, in part, because the immune system has evolved to fight microorganisms, which 
mostly have a particulate nature. Therefore, it is not surprising that particulate antigens in 
the size range of pathogens (Fig. 4a) can act as adjuvants by direct targeting of antigen 
presenting cells (O'Hagan and Valiante, 2003; Storni et al., 2005). Typically, particles are 
well recognized by the innate immune system (Fig. 4b) as foreign or as danger, hence, 
triggering the onset of an immune response. The combination of aluminum hydroxide and 
allergens, introduced for depot vaccination 70 years ago (Sledge, 1938), also consists of 
suspended aggregates or particles and thereby improve immune-stimulatory properties of 
allergens. However, in contrast to infectious particles that induce strong cell-mediated 
immune responses including strong Th1 responses (Storni et al., 2005), aluminum-based 
allergy vaccines typically give rise to Th2 responses and are sub-optimal for 
immunotherapy. Therefore, novel adjuvant particles with stronger Th1-triggering 
properties would be advantageous.  
Biodegradable polymers  
Among the most studied polymers for drug or antigen delivery is poly(lactide-co-
glycolide) (PLGA), which is biocompatible and approved by the Food and Drug 
Administration (FDA) for use in humans. There are two main properties of polymeric 
microparticles that make them particularly interesting for SIT. Firstly, they have the 
capacity to sustain the delivery of drugs or antigens (Varde and Pack, 2004). The time 
period over which this delivery is to be sustained can be controlled by using polymers with 
different physico-chemical characteristics, e.g. molecular weight and the relative 
relationship of lactide and glycolide (Johansen et al., 2000b). Secondly, and as discussed 
above, the particulate nature of microparticles provides a mechanism to deliver antigens 
efficiently to the lymphatic system, while protecting them from degradation in the 
extracellular fluids. A wide variety of proteins, peptides and even plasmid DNA have been 
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successfully encapsulated into PLGA particles, and they have been shown to induce 
protective immunity after a single subcutaneous injection (Peyre et al., 2004; Peyre et al., 
2003). Additional features of the microparticles such as their size (Gutierro et al., 2002) 
and surface properties (Wischke et al., 2006) (Martínez Gómez et al., paper submitted) can 
be modified to influence the type of immune response.  
 
Figure 4. (a) Poly (lactide-co-glycolide) microspheres photographed by scanning electron microscopy 
(bar=10 µm). Photograph courtesy of E. Wehrli, ETH Zürich (Zürich, Switzerland). (b) In vitro cultivated 
macrophages (RAW) that have engulfed microspheres of 2–5 µm size (bar=10µm). Photograph courtesy of Y. 
Men, ETH Zürich (Johansen et al., 2000a). 
 
Over the last years encapsulation of several allergens into PLGA micro/nanoparticles 
has been described. Encapsulation of Ole e 1, the major olive pollen allergen, showed no 
detrimental effect on the integrity and antigenicity of the allergen (Batanero et al., 2002). 
Moreover, immunization of mice with encapsulated Ole e 1 enhanced Th1-like responses 
as compared to Ole e 1 adsorbed on alum (Batanero et al., 2003). A recent study in mice 
showed that the prophylactic intranasal administration of PLGA microparticles containing 
a dominant T-cell epitope of Ole e 1 prevented sensitization to the whole protein. Mice had 
higher IgG2a levels and lower IgG1 and IgE as well as reduced IL-4 and IL-10 compared 
to the mice treated with empty particles. Furthermore, the airway inflammation induced 
after challenge with Ole e 1 could be attenuated after pre-treatment with the allergen-
loaded particles (Marazuela et al., 2008). 
Another prophylactic study showed that administration of PLGA loaded with plasmid 
DNA encoding for the bee venom allergen phospholipase A2 (PLA2) prior to sensitization 
protected mice against anaphylaxis. To explain the tolerance observed in sensitized mice 
after PLGA injection, the authors proposed a dual mechanism of action that involved 
initially an immune deviation from Th2 to Th1 and then IL-10-mediated suppression (Jilek 
et al., 2004). 
Schöll et al. were the first to describe the therapeutic potential of PLGA nanoparticles 
in a murine model of allergy. After a single subcutaneous injection of Bet v 1 encapsulated 
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in PLGA nanoparticles, the ongoing Th2 responses observed in sensitized mice were re-
directed towards Th1. This down-regulation of Th2 responses was associated with high 
IgG2a titers and increased IFN-γ and IL-10 production (Scholl et al., 2004).  
The surface of microparticles can be modified to target particular cell types or tissues. 
For instance, the functionalization of particles with lectins, which bind to specific 
carbohydrate moieties on the glycocalyx of cellular membranes, have been used for oral 
delivery and mucosal targeting of allergens (Gabor et al., 2004; Lavelle, 2006). Bet v 1 
loaded PLGA microparticles have been covalently linked to wheat germ agglutinin (Walter 
et al., 2004) or Aleuria aurantia lectin (Roth-Walter et al., 2005). Such particles did not 
only protect the allergen from rapid degradation in the gastrointestinal tract but they also 
prolonged antigen release at the intestinal site and induced stronger allergen-specific Th1 
responses than uncoated particles or the naked allergen. 
Alternatively, the co-encapsulation of antigens and immunostimolatory agents has been 
shown to modulate immune responses (Antje Heit, 2007; Kazzaz et al., 2006). In this 
respect, we showed that PLGA microparticles with co-encapsulated PLA2 and CpG were 
able to induce long-lasting Th1 immune responses. Moreover, bee venom-sensitized mice 
treated with co-encapsulated PLA2 and CpG microparticles had higher IgG2a levels, which 
correlated with a better protection against anaphylaxis than mice treated with the 
encapsulated PLA2 alone or with PLA2-PLGA and admixed CpG prior to injection. The 
use of protamine to stabilize the CpG was found to further enhance the immunogenicity of 
the PLA2 and caused a more pronounced protection against anaphylaxis than when CpG 
was not stabilized (Martinez Gomez et al., 2007). 
Microparticles fabricated from poly-ε-caprolactone (PCL), showed slower degradation 
rates than PLGA particles and did not generate an acidic micro-environment, which could 
damage encapsulated antigens (Lemoine et al., 1996). However, so far only one study has 
evaluated the potential of PCL particles for allergy vaccines. In OVA-sensitized mice, 
treatment with OVA in PCL particles or adsorbed to aluminum salts induced similar levels 
of IgG but aluminum induced higher IgE levels. Consequently, mice treated with OVA in 
PCL had reduced histamine secretion and body temperature drop after a challenge with a 
high dose of OVA (Roman et al., 2007). 
The synthetic copolymer poly(methyl vinyl ether-co-maleic anhydride) (PMVE/MAH, 
which is commercially branded as Gantrez® AN) is widely used for pharmaceutical 
purposes such as a thickening and suspending agent, a denture adhesive and as adjuvant for 
transdermal patches (Arbos et al., 2002). PMVE/MAH is a biodegradable polyanhydride, 
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which could be an appropriate copolymer to simplify the preparation of ligand–
nanoparticle conjugates and for the preparation of particulate dosage forms with 
bioadhesive or mucoadhesive properties. The potential of Gantrez® nanoparticles as an 
adjuvant for oral allergen immunotherapy has been evaluated in a mouse model of allergy 
(Gomez et al., 2007). Increased levels of both IgG1 and IgG2a were found in naïve mice 
after the oral administration of OVA-entrapped nanoparticles as compared to OVA in 
solution. The same study confirmed the potential of Gantrez® nanoparticles to protect mice 
from anaphylaxis in a therapeutic allergy model. OVA-sensitized mice treated with the 
OVA-entrapped nanoparticles were 100% protected against mortality in a challenge with a 
high dose of OVA, whereas only 40% of mice treated with OVA in solution were 
protected. 
Carbohydrate-based particles  
Three clinical studies in the mid-1990s evaluated the capacity of particles made of a 
sugar-starch core, coated with ragweed allergen extract, and then enterocoated with 
methacrylic acid copolymer, for oral administration (Litwin et al., 1996; Litwin et al., 
1997; Van Deusen et al., 1997). The patients that could tolerate a high dose of the 
encapsulated allergen extract had significantly decreased allergic symptoms, developed 
high titers of ragweed IgG, had an initial increased of IgE, down-regulated the expected 
seasonal increase in nasal specific IgA, and had decreased nasal sensitivity after a 
provocation test. Despite the encouraging results, more than ten years have passed without 
any further studies published using such particles. 
Chitin is the second most abundant natural polysaccharide. It consists of N-acetyl-D-
glucosamine units, and is the major component of the cell wall of fungi and the exoskeleton 
of crustaceans and insects. Its derivative chitosan is commercially obtained by 
deacetylation of chitin. It is biocompatible, biodegradable and bioadhesive, it readily binds 
to negatively charged surfaces like those of mucosal membranes, enhancing the transport of 
polar drugs across epithelial surfaces (Singla and Chawla, 2001). 
Chitin-based particles of 1-10 µm size can be phagocytosed by macrophages through 
the mannose receptor, and are potent stimulators that promote Th1 immune responses 
(Shibata et al., 1997). Orally administered chitin particles down-regulated serum IgE and 
lung eosinophilia in a mouse model of ragweed allergy (Shibata et al., 2000). Another 
study revealed down-regulation of allergic responses to Aspergillus fumigatus and 
Dermatophagoides pteronyssinus after intranasal administration of chitin microparticles. 
    Chapter 1 
 
   
37
Elevated intracellular levels of IFN-γ and TNF-α and reduced IL-4 during allergen 
challenge were found, suggesting a modulation of the immune response from Th2 to Th1 
(Strong et al., 2002). This beneficial effect of chitin particles was also observed in 
asthmatic mice (Ozdemir et al., 2006).  
Chitosan particles do not induce by themselves Th1 cytokines in the way chitin 
particles do, but they can complex DNA and effectively protect it from degradation 
(Borchard, 2001; Mansouri et al., 2004; Richardson et al., 1999). This property has been 
successfully exploited in pre-clinical studies. The complex of chitosan and peanut or house 
dust mite allergen-plasmid DNA induced immunological protection in murine models of 
peanut (Roy et al., 1999) and house dust mite (Chew et al., 2003) allergies. In addition, 
prophylactic as well as therapeutic treatment of asthmatic mice with plasmid IFN-γ 
complexed to chitosan nanoparticles resulted in effective reduction of allergen-induced 
airway inflammation and airway hyper-responsiveness. It was suggested that STAT4 
signaling was involved in the mechanism of action of chitosan particles (Kumar et al., 
2003).  
Carbohydrate-based particles (CBP) made of sepharose with a size diameter of 2 µm, 
have been proposed as an alternative to aluminum salts as adjuvant for SIT. Allergens can 
be covalently coupled with a high density without altering their immunological properties 
via cyanogen bromide activation of the particles. Phl p 5b, a major timothy grass pollen 
allergen, coupled to CBP was tested in mice and showed elevated IFN-γ production and 
IgG2a/b levels, indicating a polarized Th1 response and did not cause granulomatous tissue 
reactions as compared to alum-bound allergen. Moreover, the CBP-Phl p 5-induced 
antibodies cross-reacted with five allergens from other grass species and were able to 
inhibit binding of human IgE to the allergen (Gronlund et al., 2002). To assess the 
influence of CBP on the nature of the T cell responses, the in vitro effect of CBP-Fel d 1 on 
human monocyte-derived dendritic cells (MDDCs) from healthy individuals was studied. 
The MDDCs readily phagocytosed the CBP and up-regulated CD86 but did not induce 
maturation of these cells. The increased release of TNF-α and IL-8 induced by the CBP-Fel 
d 1 was similar to that induced by naked Fel d 1. The authors suggested that CBP-couple 
allergen induced a semi-mature state of DCs, which could probably be associated with 
mixed Th1/Th2 responses or a regulatory response (Andersson et al., 2004).  
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Liposomes 
Liposomes are small vesicles composed of naturally-derived phospholipids that are 
non-toxic and biodegradable. They can provide a depot effect after subcutaneous injection 
and act as potent immunological adjuvants, including the induction of Th1 immune 
responses. Liposomes have little allergenic potential (Arora and Gangal, 1991), and 
therefore, they have been proposed as carriers and immuno-adjuvants for allergens (Audera 
et al., 1991). 
The modulation of allergen-specific responses to mite allergens encapsulated in 
liposomes has been studied both in mice and humans. The encapsulation of a recombinant 
precursor form of Der p 1, ProDer p 1, from the major mite allergen Dermatophagoides 
pteronyssinus, into cationic liposomes made of DiC14-amidine, prevented allergic 
responses to house dust mite allergens (Jacquet et al., 2005). The complexation of the 
allergen to the liposome was necessary to induce optimal responses. Naïve mice 
immunized with DiC14-amidine/allergen liposomes induced specific IgG2a antibodies but 
no IgE antibodies, moreover, IL-5 levels were reduced and IFN-γ levels increased. Similar 
results were obtained by encapsulating the D. siboney allergen into liposomes made of 
dipalmitoyl phosphatidylcholine (Calderon et al., 2006). Mice immunized with the 
encapsulated allergen had increased serum IgG2a/IgG1 ratio and reduced cellular 
infiltration in the lungs when compared to aluminum-adsorbed allergen.  
In humans a double-blind, placebo-controlled trial using liposomes with encapsulated 
extract of D. pteronyssinus in asthmatic patients, showed less allergic symptoms and lower 
medication scores in the allergen-liposome group than in the control group receiving empty 
liposomes (Basomba et al., 2002). Patients receiving liposomal allergen also showed 
reduced immediate skin sensitivity, reduced late skin responses, as well as decreased 
bronchial sensitivity. Serum levels of specific IgG, especially IgG4, increased throughout 
the treatment, whereas IgE levels only increased transiently at the beginning of the 
treatment and then declined to baseline levels. Although the treatment was well tolerated 
with a low rate of systemic reactions and the build-up phase was reduced from the 13 
weeks of conventional SIT to 8 weeks, no follow-ups were reported and no similar studies 
have since been published. 
Virus-like particles (VLPs) 
Some viral proteins, e.g. the hepatitis B core antigen and the bacteriophage capsid 
protein Qβ, spontaneously assemble into highly repetitive structures named virus-like 
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particles (VLPs). The presentation of an antigen in a highly ordered and repetitive manner 
induces strong antibody responses in mice, whereas the same antigen presented as a 
monomer is not immunogenic (Bachmann et al., 1993; Jegerlehner et al., 2002). Many 
fungi contain mycoviruses that have a protein p1 from the transposon Ty1, which can also 
assemble into VLPs. In fact, VLPs derived from this p1 protein have been used to carry 
allergenic peptides from Der p 1 (Hirschberg et al., 1999) and Asp f 2 from Aspergillus 
fumigatus (Svirshchevskaya et al., 2002). The immunization of previously Der p 1-
sensitized mice with VLP carrying the immunodominant epitope of Der p 1 inhibited IL-5 
production and reduced allergen-specific T cell proliferation. This suppression was CD4 
mediated and no increase in IFN-γ levels was observed (Hirschberg et al., 1999). After a 
single injection of VLPs expressing a dominant T cell epitope of Asp f 2, decreased, 
although only transient, antigen-specific T and B cell responses were observed 
(Svirshchevskaya et al., 2002). More recently, the first human testing of Der p 1 covalently 
coupled to VLPs derived from the bacteriophage Qβ revealed good safety and strong 
immunogenicity (Kundig et al., 2006). 
 
Antibodies 
 
The humanized monoclonal anti-IgE antibody, omalizumab, was developed for the 
treatment of allergic diseases. Omalizumab binds to the Cε3 region of free IgE and thereby 
reduces its level in serum and down-regulates IgE receptors. Omalizumab reduced 
eosinophils, mast cells, T and B cells in nasal and bronchial tissues (Holgate et al., 2005). 
Moreover, the use of omalizumab as an add-on therapy to increase efficacy of other 
treatments has been described in several studies. A meta-analysis of seven studies 
conducted in patients with severe persistent asthma indicated that the addition of 
omalizumab to asthma treatment significantly reduced the asthma exacerbation rate and the 
incidence of emergency visits (Bousquet et al., 2005). A number of studies have assessed 
the potential of omalizumab in combination with SIT for allergic rhinitis. A recent double-
blind, placebo-controlled trial using concomitantly omalizumab and rush immunotherapy 
in ragweed allergic patients showed that patients receiving the combined treatment had 
reduced seasonal allergic rhinitis severity scores and fewer adverse events than patients 
with only SIT (Casale et al., 2006). Further analysis of sera from those patients showed that 
IgG4 was only increased in SIT treated patients. Moreover, when SIT was used alone, only 
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partial inhibition of allergen-IgE binding was observed while treatment with omalizumab 
completely inhibited allergen-IgE binding (Klunker et al., 2007). This inhibition prevents 
binding of allergen-IgE complexes to the IgE receptors on mast cells and basophils 
reducing the release of mediators that cause the allergic reaction. An additional mechanism 
of action suggested for the anti-IgE treatment is the inhibition of IgE-mediated activation of 
allergen-specific T cell by antigen presenting cells, which express low and high affinity IgE 
receptors (van Neerven et al., 2006). 
An anti-idiotype chimeric human IgG1 directed against IgE, 2G10, has also been 
shown to inhibit basophil activation (Wigginton et al., 2008). In contrast to omalizumab, 
the 2G10 antibody exert its effect by binding to surface bound IgE antibodies and cross-
linking with the inhibitory receptor FcγRIIb receptor, which then inhibits degranulation of 
sensitized mast cells and basophils. 
Other antibodies have been tested for their adjuvant or immunomodulatory effects, 
especially in therapeutic vaccination against chronic diseases or for the treatment of cancer 
or autoimmune diseases (Brekke and Sandlie, 2003). Such antibodies are typically directed 
towards cytokine receptors. Due to their key role in the pathophysiology of allergy and 
asthma, the cytokines derived from Th2 lymphocytes such as IL-4, IL-5, IL-9, IL-13 and 
IL-25 are especially interesting for SIT. IL-4 plays a critical role in the synthesis of IgE by 
B-lymphocytes, as well as its involvement in eosinophil recruitment to the airways. A 
unique function of IL-4 is to promote the differentiation of Th2 cells and therefore it acts at 
a proximal and critical site in the allergic response, making IL-4 an attractive target for 
inhibition. Indeed, IL-4 blocking antibodies inhibited allergen-induced airway hyper-
responsiveness, goblet cell metaplasia and pulmonary eosinophilia in a murine model 
(Gavett et al., 1997).  
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Table 1. Strategies to improve SIT efficacy, safety and compliance. 
SIT strategy Method/Material Advantages Disadvantages 
Route of 
administration 
Subcutaneous 
 
Sublingual SLIT; 
(Spit or Swallow) 
 
Oral 
 
Nasal 
Intranodal 
High success rate 
 
Safety 
Convenience 
 
Safety 
Convenience 
Targeting rhinitis? 
Safety 
Short duration 
Compliance 
High efficacy 
Low dose 
Adverse events 
Long duration 
Low efficacy 
Long duration 
High doses required 
Long duration 
High doses required 
Safety? 
Ultrasound required 
Allergen  Allergen extracts 
 
Purified proteins 
Recomb. Proteins 
 
Synthetic 
peptides 
DNA 
Contains all allergens 
Mostly cheap 
Well defined 
compositions 
Structure flexibility 
Targeting sequences 
may be added 
Strong T-cell 
stimulation 
Safety 
Safety 
 
Ill-defined compositions 
 
Purification expensive 
Costly production 
Only major allergens 
 
No B-cell stimulation 
Efficacy? 
Poor efficacy in humans 
Poor public acceptance 
of “Gene therapy” 
Adjuvants Mineral salts 
(Al3+ or Ca2+) 
TLR ligands 
 
Particles 
(Nano-/Micro-) 
Depot 
General applicability 
Strong Th1-
triggering 
 
Draining to LN 
Depot 
Allergen stabilisation 
Poor Th1-triggereing 
 
No depot 
Toxicity 
Safety? 
Antibodies Anti-IgE 
 
Cytokines 
Safety 
Fast onset 
Th1-triggering 
Strong immune 
modulation 
Potency 
Weak therapeutic effect 
Costly treatment 
Unspecific immune 
modulation 
Toxicity 
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CONCLUSIONS 
 
Subcutaneous allergen-specific immunotherapy is clearly established as an efficacious 
form of treatment for allergies, with the potential to modify the natural course of allergic 
rhinitis and possibly prevent the development of asthma in children. It is widely used 
around the world for a broad range of allergic conditions, including rhino-conjunctivitis, 
conjunctivitis, and asthma. For patients in whom pharmacotherapy fails to provide 
adequate symptom control, immunotherapy provides an effective alternative treatment 
option. Also, for patients with insect sting allergy, immunotherapy may be the only viable 
prophylactic treatment option.  
The use of new technologies appears to offer the possibility for reducing the duration of 
the therapy, the number of injections required and, at the same time, improving safety. 
Research into alternative administration routes, e.g. sublingual and intranodal, is producing 
encouraging results. The convenience and safety profile are clearly superior to that of 
subcutaneous immunotherapy. If proved efficient, these new strategies should improve 
compliance, which is a critical issue in SIT. Especially children would benefit from 
substituting subcutaneous SIT with less invasive methods such as sublingual therapy. If 
immunomodulators and improved adjuvants can replace alum to increase efficacy with no 
loss of safety, this may eventually lead to injections becoming unnecessary and could even 
be used in a primary care setting rather than specialized allergy clinics. Immunotherapy 
may become suitable for more general, widespread use, particularly in children. 
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ABSTRACT 
Allergen-specific immunotherapy (SIT) is the only curative treatment for allergic 
patients and is typically performed by subcutaneous allergen injections. Although the 
prevalence of allergic diseases has doubled over the last 20 years, the number of patients 
undergoing SIT remains low, mainly due to its long duration and the risk of adverse events 
associated with subcutaneous SIT. In order to improve SIT safety and its attractiveness 
among patients, alternative routes of administrations have been proposed, e.g. the 
sublingual and nasal. The present study evaluated intralymphatic allergen administration as 
a novel method of SIT. In mice, direct injection of adjuvanted allergens into inguinal 
lymph nodes strongly enhanced allergen immunogenicity as compared to subcutaneous 
injections. Moreover, only intralymphatic injections induced production of IgG2a 
antibodies and it resulted in increased cytokine secretion than did subcutaneous 
administrations. Finally, intralymphatic immunotherapy caused improved protection 
against anaphylaxis than subcutaneous SIT. One reason for the superiority of 
intralymphatic injections was that this directs the antigen more efficiently to secondary 
lymphatic organs than subcutaneous injections, which caused antigens to remain at the 
injection site or to drain to the liver. In conclusion, direct allergen administration into 
lymph nodes increase SIT efficacy and therefore, represent a promising alternative to 
conventional SIT both in terms of efficacy and patient compliance. 
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INTRODUCTION 
Treatments with corticosteroids and antihistamines can palliate symptoms associated 
with type I allergies but can not cure the disease. The only long-lasting treatment is 
allergen-specific immunotherapy (SIT), which is typically performed by subcutaneous 
administration of allergens. Despite the high efficacy of SIT, e.g. in Hymenoptera-venom 
allergy, the efficacy reaches 80-95% (Golden, 2005), only approximately 5% of allergic 
patients choose SIT as a first-line therapy, mainly due to the long duration of the treatment 
(3-5 years), the high number of injections required (30-80), and the risk of adverse allergic 
reactions. Therefore, there is a recognised interest in improving the current methods of SIT.  
Numerous studies have investigated new strategies to optimise the allergen molecules 
(Jutel et al., 2005; Larche, 2007; Riemer et al., 2004), the adjuvants used (Creticos et al., 
2004; Johansen et al., 2005b; Santeliz et al., 2002), the dosage form (Jilek et al., 2004; 
Kundig et al., 2006; Martinez Gomez et al., 2007), as well as the route of allergen 
administration (Barbey et al., 2004; Bohle et al., 2007; Razafindratsita et al., 2007).  
Vaccines are typically administrated by subcutaneous injections. However, immune 
responses are induced in secondary lymphoid organs, where professional antigen 
presenting cells (APCs) present antigenic epitopes to the residing lymphocytes. It has been 
demonstrated that antigen localisation regulates immune responses and that even large 
amounts of antigens can be ignored by the immune system if they remain outside the 
organized lymphoid tissues (Zinkernagel, 2000; Zinkernagel et al., 1997). Hence, direct 
administration of antigens to lymph nodes would be a more efficient route to deliver 
antigens to the cells from the immune system. This concept has been shown valid for the 
administration of plasmid DNA (Maloy et al., 2001) and peptides (Johansen et al., 2005a) 
for the stimulation of strong and protective T-cell responses. In the present study, we 
compared direct intralymphatic and subcutaneous administration of allergens in mice as a 
means for improving SIT efficacy.  
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METHODS 
Immunisation protocols 
CBA female mice (6-8 weeks old, from Harlan, Horst, The Netherlands) were 
immunised three times with two week intervals in between by injection with the bee venom 
major allergen phospholipase A2 (PLA2, from Sigma-Aldrich, Buchs, Switzerland) or a 
recombinant Fel d 1 cat major allergen. Fel d 1 was engineered on a pQE30 expression 
vector (Qiagen, Hilden, Germany) containing a N-terminal [His]6-tag for protein 
purification, and were produced in Escherichia coli as described (Crameri, Allergy 2007). 
The allergens were mixed with aluminium hydroxide (Alhydrogel 3%, from Brenntag 
Biosector, Fredrikssund, Denmark) and saline one hour before injection into the inguinal 
lymph node (i.l.) (Johansen et al., 2005a), subcutaneously (s.c.) or intraperitoneally (i.p.). 
The doses of aluminium hydroxide were 90 and 450 µg, for i.l. and s.c. or i.p. injections, 
respectively, and the injection volumes were 10 and 50 µl. Serum was prepared from tail 
vein blood drawn at different time points and frozen at -20°C until analysed by ELISA. 
Alternatively, the two routes of administration were tested in a therapeutic model in 
CBA mice that were first sensitised to cat fur allergens by six weekly intraperitoneal (i.p.) 
injections of cat fur allergen extract from Stallergènes (Fresnes, France). The allergen 
extract (1 µg/dose) was adsorbed to aluminium hydroxide (900 µg/dose) and injected in a 
volume of 100 µl. Subsequently, the mice were desensitised with 1 µg Fel d 1 by i.l. or s.c. 
injections as described above. For induction of anaphylaxis, sensitised mice were 
challenged three weeks after the last desensitisation with 30 µg of cat fur allergen extract in 
saline (50 µl i.p.), and the body temperature was measured with a calibrated digital 
thermometer before and 30 minutes after the challenge. 
Antibody measurements 
For antibody detection, 96-well microtitre plates (Nunc Maxisorb, Basel, Switzerland) 
were coated with 5 µg/ml of PLA2 (Sigma-Aldrich) or 1 µg/ml cat fur allergen extract 
(Stallergènes) in carbonate buffer and incubated overnight at 4°C. After blocking the plates 
with 2.5% non-fat dry milk in PBS-0.05% Tween-20 (PBSTM), serial dilutions of 
individual sera in PBSTM were added to the plates, and incubated for 2 h. Then plates were 
incubated with biotinylated goat anti-mouse IgG1 or IgG2a (BD Pharmingen, San Diego, 
CA, USA) in PBSTM, followed by incubation with streptavidin-conjugated horseradish 
peroxidase (BD Pharmingen). In the last step, plates were incubated with the enzyme 
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substrate 2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) di-ammonium salt 
(Sigma-Aldrich) in 1 M sodium dihydrogen phosphate. The absorption was read at 405 nm 
on a Model 550 Microplate reader (BioRad, Hercules, CA, USA). Unless otherwise 
specified, all incubations were done at room temperature and were intercepted with PBST 
washes. 
For detection of PLA2-specific IgE antibodies, plates were coated with 2 µg/ml of anti-
mouse IgE capture antibody (BD Pharmingen). As secondary reagent for binding to mouse 
serum, an in-house biotinylated PLA2 was used at 3 µg/ml.  
Cytokine-secretion assay  
CBA mice were immunised three times by i.l. or s.c. injection with 1 µg of Fel d 1, as 
described above. One week after the last injection, spleens were isolated and single-cell 
suspensions prepared. Erythrocytes were removed by lysis (red blood cell lysis buffer, 
Sigma-Aldrich), and triplicates of 8x105 cells were cultured with 10 µg/ml LoTox Fel d 1 
from Indoors Biotechnology (Warminster, United Kingdom) or left un-stimulated in 200 µl 
of IMDM supplemented with 5% FCS, sodium pyruvate, L-Glutamine, penicillin and 
streptomycin. The cytokines secreted in the supernatant were measured using the DuoSet 
ELISA from R&D Systems (Abingdon, United Kingdom). Supernatants were collected 
after 20 h for IL-2 determination and after 72 h for determination of IL-4, IL-10 and IFN-γ.  
Biodistribution 
To compare the relative biodistribution of i.l. and s.c. administered proteins, CBA mice 
were injected with 99mTc pertechnetate-labelled human immunoglobulin 
(TechneScan® HIG) from Mallinckrodt Medical B.V. (Petten, the Netherlands); the half 
life of 99mTc is approx. six hours. The radioactive protein was injected in the inguinal 
lymph node or subcutaneously in the inguinal region at 3 MBq per dose. Four animals each 
were euthanised 90 min, and 17 hours after injection. Lungs, spleen, liver and inguinal 
lymph nodes were dissected, and analysed directly in a Cobra II gamma counter (Packard 
BioScience, Dreieich, Germany). The absolute distribution to each organ was expressed as 
radioactive count per minutes (cpm). 
Statistics 
Differences between independent groups were tested by non-parametric statistical 
analysis. Data were presented as means ± standard error and compared using a two-sided 
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independent Mann-Whitney U test or Kruskal-Wallis one-way analysis of variance with 
Dunn’s multiple comparison test. The significance level was set at 5%. 
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RESULTS 
Intralymphatic immunisation induced strong humoral responses at lower allergen 
doses 
To asses the influence of the route of administration in the immunogenicity of 
allergens, CBA mice were immunised with 0.1, 1 or 10 µg of the bee venom major allergen 
PLA2 by three fortnightly s.c. or i.l. injections. As illustrated in Figure 1, i.l. administration 
of 0.1 µg PLA2 was sufficient to induce of high PLA2-specific IgG2a titers. Comparable 
titers upon s.c. or i.p. injections were obtained by injection of 10 µg PLA2. In contrast, 
significant titers of IgE were only observed after i.p. injection of PLA2.  
 
Figure 1. Bee venom PLA2-specific IgG2 and IgE antibodies measured by ELISA. Mice were immunized 
thrice with 0.1, 1, or 10 µg bee venom PLA2 adsorbed on aluminium hydroxide by intralymphatic (●), 
subcutaneous (□) or intraperitoneal (U) injections. Mice were bled at indicated time points and the sera 
analysed of PLA2-specific IgG2 and IgE. The data are illustrated as means ± SEM (n = 5). 
 
The direct injection into inguinal lymph nodes was also tested using the perennial cat 
fur major allergen Fel d 1, which was injected in mice at two doses, 0.1 and 1 µg, and 
compared with the s.c. injection of 10 µg Fel d 1. As illustrated in Figure 2, comparable 
high IgG1 levels were induced in all three groups of mice, independent of the route of 
administration or the dose used. However, only mice that received Fel d 1 by i.l. injection 
produced IgG2a antibodies, and 0.1 µg was sufficient to stimulate a strong response. The 
response remained stable for at least eight weeks after the last injection (data not shown). 
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Figure 2. Cat allergen-specific IgG1 and IgG2a antibodies measured by ELISA. Mice were immunized thrice 
intralymphatically with 0.1 µg (●) or 1 µg (○) of Fel d 1 or subcutaneously (□) with 10 µg Fel d 1. The sera 
were analyzed after 2, 5 and 8 weeks of the last injection. The data from the last time point are illustrated here 
and expressed as means ± SEM (n = 4). One representative out of two independent experiments is shown. 
 
Intralymphatic injections enhanced cytokine production 
To evaluate the effect of the route of administration on the T-cell function, mice were 
immunised s.c. or i.l. with recombinant Fel d 1 protein. After seven days, splenocytes were 
re-stimulated in vitro with low endotoxin Fel d 1. The secretion of IL-2 was determined in 
the supernatants after 20 h, while IL-4, IL-10 and IFN-γ were measured after 72 h (Fig. 3). 
The secretion of all four cytokines was higher in cultured cells from mice that had been 
immunised by i.l. allergen administration.  
 
Figure 3. Cytokine secretion assay. Groups of four mice were immunised thrice with 1 µg of Fel d 1 
intralymphatically or subcutaneously, and the splenocytes were analyzed for secretion of different cytokines 
after in vitro re-stimulation with 10 µg/ml of Fel d 1. The cytokine concentrations in supernatant are shown 
after subtraction of spontaneous secretion from non-stimulated splenocytes and as measured by ELISA. 
Statistical differences are indicated when p<0.05 as analysed by the Mann Whitney U test (n = 4). 
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Immunotherapy with intralymphatic Fel d 1 enhanced protection against anaphylaxis 
Mice sensitised to cat fur allergen extract have high levels of serum IgE and IgG1, but 
no detectable IgG2a. Upon desensitisation with the Fel d 1 allergen, the i.l. route of 
administration induced a higher IgG2a response than did s.c. injections (data not shown). 
Three weeks after completed immunotherapy, mice were challenged with a high dose of cat 
fur allergen extract and subsequently monitored for anaphylaxis. As illustrated in Figure 4, 
immunotherapy performed by i.l. administration of the Fel d 1 caused significant 
improvement of the allergic status, these mice showed significantly less anaphylactic 
reaction than sensitised mice that did not received immunotherapy (p=0.048). In contrast, 
immunotherapy by means of three s.c. injections of the allergen was not sufficient to 
ameliorate anaphylactic reactions in sensitised mice. 
 
Figure 4. Allergen-specific immunotherapy and test of anaphylaxis. Groups of four mice were sensitised 
against Fel d 1 by i.p. injections of cat fur allergen extract, and then treated by i.l. or s.c. injections of 
recombinant Fel d 1. Four weeks after the last SIT injection, mice were challenge with 30 µg of cat fur 
allergen extract. The negative control group contained naive mice, while the positive control was a group of 
sensitised mice that did not receive immunotherapy. The body temperature drop was measured before and 30 
minutes after the challenge, and the groups were compared by Kruskal-Wallis with a Dunn’s post test of 
variance (* p<0.05). 
 
Preferential distribution to spleen upon intralymphatic injection 
One possible explanation to the observed benefit of i.l. immunisation and 
immunotherapy over s.c. injections could be that the latter administration route does not 
allow complete drainage of the allergen into secondary lymphatic tissues. This difference in 
allergen dose available for stimulation of allergen-specific lymphocytes may also lead to 
the preferential Th1 immune responses observed after i.l. allergen administration. Hence, to 
analyse the fate of an injected protein as a function of administration route, mice received 
i.l. or s.c. injections of a human immunoglobulin labelled with radioactive technetium. The 
analysis of the radioactivity in different tissues 90 min after the injection revealed that the 
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i.l. administration lead to a preferential accumulation of radioactivity in secondary 
lymphatic organs such as the inguinal lymph nodes and spleen (p<0.05). In contrast, s.c. 
administered protein more strongly drained to the liver (p<0.05). Seventeen hours after 
injection, significantly more radioactivity was recorded in the inguinal lymph node of i.l. 
than in the s.c. injected mice (p<0.05).  
 
Figure 5. Biodistribution of intralymphatically and subcutaneously injected protein. Groups of four mice 
were injected with 99mTc-labelled human immunoglobulin directly into an inguinal lymph node (open bars) 
or subcutaneously in the inguinal region (filled bars). After 90 min and after 17 hours, the mice were 
euthanized, and the inguinal lymph nodes, the spleen, the lungs as well as all liver lobes were isolated and 
immediately assayed for gamma emmision. Statistical differences are indicated when p<0.05 as analysed by 
Mann Whitney U test (n = 4). 
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DISCUSSION 
There is a high prevalence of allergic diseases in industrialised countries, with up to 
20% of the population suffering from type I hypersensitivity reactions (Bauchau and 
Durham, 2004). The only curative treatment available for these patients is SIT (Durham et 
al., 1999). However, the benefits of SIT are arguably questionable with regard to the long-
term commitment of the patient, the high treatment costs, and the evident risk of allergic 
adverse reactions associated with the immunotherapy (Casale, 2004). One important 
approach for improving SIT focuses on the route of administration of allergens. In this 
respect, sublingual immunotherapy (SLIT), in which the allergen is given as soluble tablets 
or drops, and local nasal immunotherapy have proven clinically effective (Bousquet et al., 
1998; Bousquet et al., 1999; Nelson, 2005; Passalacqua et al., 2004). However, the 
treatment duration of SLIT and nasal SIT remains similar to that of current subcutaneous 
SIT (Canonica and Passalacqua, 2003) and the allergen dose is at least 50-100 times higher 
than the dose needed for subcutaneous immunisation (Bousquet et al., 2001). 
The results presented in the current study showed that direct intralymphatic injections 
enhanced immunogenicity of allergens as compared to the classical SIT by the 
subcutaneous route of administration. These results are in line with already published data 
showing enhanced immunogenicity in both plasmid DNA (Maloy et al., 2001) and peptide 
(Johansen et al., 2005a) vaccination after direct intralymphatic injections. In addition, 
intranodal administration required at least 100 times less antigen (Maloy et al., 2001) or 
immune stimulatory molecules (von Beust et al., 2005) to induce potent cytotoxic T-cell 
immune responses than subcutaneous antigen administration. In the present study, 
intralymphatic immunisation was shown to stimulate humoral immune responses 
comparable to that of subcutaneous SIT, but with only 1% of the allergen dose. Moreover, 
while subcutaneous SIT only induced IgG1, the Th2-associated subclass, intralymphatic 
allergen administration also stimulated Th1-associated specific IgG2a antibodies. The 
enhanced humoral immune responses observed after intranodal immunisation were 
furthermore supported by a general increase in the secretion of cytokines after re-
stimulation of the lymphocytes in vitro.  
The geographical concept of immune reactivity emphasises the importance of antigen 
localisation (Zinkernagel, 2000). As conventional T- and B- cell responses can only be 
induced in organised lymphoid tissues, the direct injection of antigens into subcutaneous 
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lymph nodes would obviously facilitate the stimulation of stronger immune responses. 
Against early older assumptions, studies have also shown that antigen presentation does not 
have to take place in peripheral tissues, such as the skin, but that dendritic cells and other 
professional antigen-presenting cells residing in the lymph nodes and the spleen are 
capable of presenting antigen epitopes and to stimulate strong B- and T-cell responses 
(Heinzerling et al., 2006; Johansen et al., 2005a; Maloy et al., 2001; von Beust et al., 2005). 
Hence, the reason why the intralymphatic route of immunisation was more efficient 
than subcutaneous allergen administration in stimulating strong immune responses, 
especially of the Th1-type, is most likely a reason of stochastic matter. As illustrated in the 
biodistribution of radioactive labelled proteins, a few percent of the subcutaneously 
injected material drained and remained in the lymphatic tissue (spleen and inguinal lymph 
nodes), while most of the material ended up in the liver. In contrast, after intralymphatic 
administration, the entire allergen dose is available for antigen-presentation in the lymph 
node. This, and the fact that high antigen doses favours Th1-like immune responses 
(Powell et al., 2007; Ruedl et al., 2000) explain why efficient lymphatic targeting of the 
allergen is important for the stimulation of protective immune responses in the allergen-
specific immunotherapy. Indeed, such targeting has been applied by other means, for 
instance by using allergens bound to so-called virus like particles that very efficiently drain 
to the lymph nodes (Kundig et al., 2006; Vania Manolova, 2008). In the same way other 
kind of particles or carrier molecules can be imagined effective in strengthening 
immunotherapy solely by the fact that they bring more allergen into the secondary 
lymphatic tissue.  
Another key point in immune reactivity is the duration of receptor stimulation in the 
immunological synapsis between lymphocytes and antigen-presenting cells. If the 
stimulation threshold is not reached, the lymphocytes will not be activated or only poorly 
activated (Giandomenica Iezzi, 1999; Huppa et al., 2003). Hence, as the intralymphatic 
allergen administration provides a larger effective allergen dose to the immunological 
synapsis, this increases the probability of obtaining sufficient synapsis time and 
lymphocyte stimulation/activation as compared to subcutaneous immunotherapy. 
An additional important benefit of intralymphatic over subcutaneous immunotherapy is 
that the former avoids direct contact with the skin mast cells and therefore, prevents local 
adverse events associated with the allergen-mediated degranulation of such cells. 
Moreover, as lower therapeutic doses are required to induce comparably strong immune 
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responses, the intralymphatic immunotherapy may further reduce the risk of local and 
systemic allergic side effects to a minimum. Recently, the intralymphatic immunotherapy 
has been tested in humans for the treatment of both grass pollen and bee venom allergies 
(Senti et al., papers in preparation), demonstrating its clinical feasibility. The injection into 
subcutaneous lymph nodes has also been applied in the treatment of other conditions 
(Spaner et al., 2006); in all these human studies, the intralymphatic injections were guided 
and documented by ultrasound.  
In closing, the intralymphatic route of administration represents a powerful tool to 
increase the efficacy of allergen-specific immunotherapy and to reduce the risk of adverse 
events as compared to conventional subcutaneous immunotherapy. In humans, this should 
potentially increase the attractiveness and compliance among patients otherwise reluctant 
to go through years and dozens of doctor visits and subcutaneous injections. 
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ABSTRACT  
Background: Current subcutaneous allergen-specific immunotherapy (SIT) leads to 
amelioration of IgE mediated allergy, but it requires numerous allergen injections over 
several years and is frequently associated with severe side effects. The aim of this study 
was to test whether modified recombinant allergens can improve therapeutic efficacy in 
SIT while reducing allergic side effects. 
Methods: The major cat allergen Fel d 1 was fused to a TAT-derived protein translocation 
domain and to a truncated invariant chain for targeting the MHC class II pathway (MAT-
Fel d 1). The immunogenicity was evaluated in mice, while potential safety issues were 
assessed by CAST using basophils from cat dander allergic patients.  
Results: MAT-Fel d 1 enhanced induction of Fel d 1 specific IgG2a antibody responses as 
well as the secretion of IFN-γ and IL-2 from T cells. SIT of mice using the modified 
Fel d 1 provided stronger protection against anaphylaxis than SIT with unmodified Fel d 1, 
and MAT-Fel d 1 caused less degranulation of human basophils than native Fel d 1. 
Conclusion: MAT-Fel d 1 allergen enhanced protective antibody and Th1 responses in 
mice, while reducing human basophil degranulation. Immunotherapy using MAT-Fel d 1 
allergen has the potential to enhance SIT efficacy and safety, thus, shortening SIT. This 
should increase patient compliance and lower treatment costs.  
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INTRODUCTION 
Allergen-specific immunotherapy (SIT) is the only causal treatment of allergies, has a 
long-lasting effect and can stop progression of the allergy to multiple sensitisations or to 
asthma. Subcutaneous SIT typically requires 30-80 injections during 3-5 years (Pichler et 
al., 2001) and bears a significant risk of allergic side effects including anaphylaxis. Hence, 
the number of injections and also the risk of allergic side effects should be reduced. Current 
efforts to enhance SIT focus on optimizing the allergen molecules (Karamloo et al., 2005; 
Larche, 2007; Saarne et al., 2005), the adjuvants (Johansen et al., 2005b; Santeliz et al., 
2002), the route of administration (Barbey et al., 2004; Bohle et al., 2007; Razafindratsita 
et al., 2007), and also their dosage form, including use of particulate delivery systems, such 
as virus like (Kundig et al., 2006) or poly(lactide-co-glycolide) particles (Martinez Gomez 
et al., 2007). 
Approaches to increase the safety of SIT include pre-treatment with anti-histamines or 
anti-IgE antibodies (Kopp et al., 2007). Safety can also be improved by disrupting IgE 
binding epitopes by heat denaturation (Johansen et al., 2005c), by chemical modifications 
to generate allergoids (García-Sellés J, 2003), using genetically engineered allergens with 
reduced IgE binding capacity (Karamloo et al., 2005; Saarne et al., 2005), or using 
synthetic peptides that do not bind IgE but stimulate T cell responses (Larche, 2007). 
However, reduced IgE binding has often been followed by reduced immunogenicity of the 
allergens (Wurtzen et al., 2007). 
We have recently proposed a new concept for allergy vaccines based on targeting the 
MHC class II antigen presentation pathway (Crameri et al., 2007). These so-called modular 
antigen transporter (MAT) recombinant allergens consist of an allergen fused to a TAT-
derived translocation peptide and to the first 110 amino-acids of the human invariant chain 
(Ii). The TAT peptide mediates cytoplasmic uptake of extracellular proteins (Fittipaldi and 
Giacca, 2005; Gump and Dowdy, 2007). Small molecules are believed to enter cells via 
electrostatic interactions in an energy-independent manner, whereas large molecules are 
taken up by energy-dependent macropinocytosis (Herce and Garcia, 2007). Early in 
biosynthesis, MHC class II αβ heterodimers assemble in the endoplasmic reticulum with 
an Ii trimer to form a nonameric complex (Roche et al., 1991). Ii binds to the MHC class II 
molecule and blocks the class II peptide binding groove until the MHC II-Ii complexes are 
transported to the endosomes where Ii is removed by proteolysis, thus permitting loading of 
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the groove with endosomal peptides (Hiltbold and Roche, 2002). Fusing the allergen to Ii 
therefore directly links the allergen with the class II pathway of antigen presentation. 
In this study, we used Fel d 1 as a model allergen and tested the influence of the above 
described modifications on immune responses in vivo. To avoid potential differences in 
distribution and pharmacokinetics of the different proteins, the allergens were administered 
directly into the inguinal lymph nodes of mice (Johansen et al., 2005a).  
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METHODS 
Allergens 
Cat fur allergen extract was purchased from Stallergènes (Fresnes, France). rFel d 1 (19 
kDa), TAT-Fel d 1 (21 kDa; with the HIV-TAT sequence GYGRKKRRQRRR) and MAT-
Fel d 1 (34 kDa; with HIV-TAT plus amino acids 1-110 of the human invariant chain) were 
engineered on pQE30 expression vectors (Qiagen, Hilden, Germany) containing an N-
terminal [His]6-tag for protein purification and were produced in Escherichia coli as 
described previously (Crameri et al., 2007). 
Immunisation protocols 
CBA female mice (6-8 weeks; Harlan, Horst, The Netherlands) were immunised thrice 
with two-week intervals by intralymphatic (i.l.) injection (Johansen et al., 2005a) with 30 
pmol of allergen, 90 µg of Al(OH)3 (Alhydrogel 3%, Brenntag Biosector, Fredrikssund, 
Denmark) and saline (10 µl) into the inguinal lymph node or by subcutaneous (s.c.) 
injection with 300 pmol of allergen, 450 µg Al(OH)3 and saline (50 µl). Moreover, the 
MAT-Fel d 1 immunisation regime was optimised by testing different doses and numbers 
of i.l. injections. Serum was prepared from tail vein blood and frozen at -20°C until 
analysed. 
The therapeutic potential of the allergens was tested in mice sensitised by 6 weekly 
intraperitoneal (i.p.) injections of 1 µg cat fur allergen extract with 900 µg Al(OH)3 in 100 
µl. Subsequently, mice were desensitised with the different allergen molecules 
administered by i.l. injections as described above. For induction of anaphylaxis, sensitised 
mice were challenged with 20 µg of cat fur allergen extract in saline (50 µl i.p.). Body 
temperature was measured with a calibrated digital thermometer before and 30 minutes 
after the challenge. 
Safety was assessed by challenging sensitised mice with 5 µM of the different Fel d 1 
allergen molecules in saline as described above.  
All animal experiments were approved by and performed according to the guidelines 
from the Swiss veterinary service authorities. 
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Antibody measurements 
For antibody detection, 96-well microtitre plates (Nunc Maxisorb, Basel, Switzerland) 
were coated with 1 µg/ml cat fur allergen extract in carbonate buffer and incubated 
overnight at 4°C. After blocking the plates with 2.5% non-fat dry milk in PBS-0.05% 
Tween-20 (PBSTM), serial dilutions of individual sera in PBSTM were added to the plates 
for 2 h. The plates were then incubated with biotinylated goat anti-mouse IgG1 or IgG2a 
(BD Pharmingen, San Diego, CA) in PBSTM, followed by incubation with streptavidin-
conjugated horseradish peroxidase (BD Pharmingen, San Diego, CA, USA). Finally, the 
plates were added the enzyme substrate 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) di-ammonium salt (Sigma-Aldrich, Buchs, Switzerland) in 1 M sodium dihydrogen 
phosphate and absorption read at 405 nm on a Model 550 Microplate reader (BioRad, 
Hercules, CA, USA). Unless otherwise specified, all incubations were done at room 
temperature and intercepted with PBST washes. 
For detection of total IgE antibodies, plates were coated with 2 µg/ml of anti-mouse IgE 
capture antibody (BD Pharmingen) at 4°C overnight. As secondary reagent to bound mouse 
serum, biotinylated anti-mouse IgE (BD Pharmingen) was used at 2 µg/ml.  
To determine the IgE binding capacity of the different Fel d 1 proteins, plates were 
coated with anti-mouse IgE (BD Pharmingen) as above, washed, blocked with PBSTM, 
and incubated  2 h with serum samples from sensitised mice. Then, cat fur allergen extract, 
rFel d 1, TAT-Fel d 1 or MAT-Fel d 1 were added at 0.6 µM and the plates incubated for 
another 90 min. Two different antibodies were then used for detection: anti-Histag-Biotin 
(Qiagen, Hombrechtikon, Switzerland) or anti-Fel d 1-Biotin (Indoors, Biotechnology, 
Warminster, United Kingdom) at 1/1000 dilution (90 min). The plates were developed 
using enzyme and substrate as described above. 
Cytokine-secretion assay  
Mice were immunised thrice by i.l. injection with 30 pmol of MAT-Fel d 1, TAT-
Fel d 1 or rFel d 1, as described above. One week later, spleens were isolated and single-
cell suspensions prepared. Erythrocytes were removed by lysis, and triplicates of 8x105 
cells/well were cultured with 10 µg/ml LoTox Fel d 1 (Indoors Biotechnology) or left 
unstimulated in 200 µl of supplemented IMDM. Supernatants were collected after 20 h for 
IL-2 determination and after 72 h for determination of IL-4, IL-10 and IFN-γ using the 
DuoSet ELISA from R&D Systems (Abingdon, United Kingdom).  
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Allergenicity in human leukocytes 
Freshly withdrawn blood from ten patients with allergy to cat dander was prepared for 
analysis by the cellular allergen stimulation test (CAST-2000 ELISA, Bühlmann 
Laboratories AG, Schönenbuch, Switzerland). Leukocytes were isolated by dextran 
sedimentation and incubated with IL-3 together with cat fur allergen extract, rFel d 1 or 
MAT-Fel d 1 at different concentrations for 40 minutes. Samples were then frozen at -80°C 
until analysed for quantification of the leukotrienes released in the supernatant. 
This single centre clinical study was performed between September and December 
2005 with patients recruited from the allergy unit of the Zurich University Hospital. 
Inclusion criteria were a clear history of cat dander allergy documented by quantitative 
Fel d 1-specific IgE ImmunoCAP determinations (Phadia, Uppsala Sweden) and positive 
skin prick test (wheal diameter ≥ 3 mm2). The study was approved by the local ethical 
review committee, performed according to GCP guidelines and the Declaration of Helsinki. 
All patients gave informed consent before entering the trial (clinicaltrials.gov Identifier: 
NCT00620880). 
Statistics 
To assess statistical variances data were analysed by non-parametric tests, i.e.Mann-
Whitney U test or Kruskal-Wallis one-way analysis of variance with Dunn’s multiple 
comparison test using shared p-values. The significance level was set at 95%. 
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RESULTS  
MAT allergens enhanced IgG2a antibody responses in mice 
All three recombinant Fel d 1 allergens induced high levels of cat allergen-specific 
IgG1 antibodies (Fig. 1a), independent on the route of administration. The IgG1 levels 
were lower for the mice injected with MAT-Fel d 1 i.l. as compared to the other i.l. injected 
proteins (p<0.05). The IgG2a responses (Fig. 1b) were significantly different between the 
three groups (p<0.05), having mice immunised with MAT-Fel d 1 or TAT-Fel d 1 higher 
IgG2a levels than rFel d 1. Moreover, the levels of IgG2a were higher upon i.l. than upon 
s.c. immunisation for all three proteins. 
The ratio of IgG2a to IgG1 is a parameter for the relative strength of Th1 to Th2 
immune responses. All ratios were higher for i.l. than for s.c. injections, indicating a 
preferential Th1 polarisation by the i.l. route (Fig. 1c). Immunisation of mice with MAT-
Fel d 1 induced significantly higher IgG2a-to-IgG1 ratios as compared to rFel d 1 (p<0.01), 
both after s.c. and i.l. administration. All antibody responses were long-lasting, and the 
IgG2a-to-IgG1 ratios remained unchanged. 
 
Figure 1. Cat allergen-specific serum antibodies of mice immunised thrice with 30 pmol intralymphatically 
(i.l.) or 300 pmol subcutaneously (s.c.) of recombinant Fel d 1 (■), TAT-Fel d 1 (○) or MAT-Fel d 1 (□). Six 
weeks after the last injection sera were analysed by ELISA for IgG1 (a) or IgG2a (b). Symbols represent 
means ± SEM (n = 8). The ratio of IgG2a to IgG1 (c) was calculated for the indicated time points at 1/400 
serum dilution as a parameter for the Th1/Th2 balance. Statistical analyses were done using the Kruskal-
Wallis test with Dunn’s multiple comparison posttest (** p < 0.01; * p < 0.05), differences shown in the 
graphs are applied to rFel d 1 and MAT-Fel d 1. 
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Three intralymphatic immunisations with 0.1 µg MAT-Fel d 1 were sufficient to induce 
both IgG1 and IgG2a antibodies (Fig. 2a). The immune responses significantly increased 
for both subclasses at 1 µg (p<0.05), which represented an optimum, as no further increase 
of the response was observed at 10 µg. At a dose of 1 µg, optimal immunisation regimen 
was achieved with three i.l. injections (Fig. 2b). One injection was inferior (p<0.05), while 
four injections did not further improve the response. 
 
Figure 2. Cat allergen-specific IgG2a and IgG1 during the optimisation of the immunisation regime. (a) Mice 
were immunised thrice intralymphatically with 0 (X), 0.01 (▼), 0.1 (●), 1 (▲) or 10 µg (□) of MAT-Fel d 1. 
Sera were analysed at 2, 5 and 8 weeks after the last injection. (b) Mice received from either no injections 
(X), or 1 (▼), 2 (●), 3 (▲) or 4 (□) intralymphatic injections of MAT-Fel d 1, respectively. Antibody levels 
were measured at 2, 4, 6 and 8 weeks after the last injection. For both experiments antibody levels are 
expressed as mean optical densities at 1/100 (a) or 1/400 (b) sera dilutions ± SEM (n = 5). 
 
Vaccination with MAT-Fel d 1 allergen increased Th1 cytokine production 
Upon re-stimulation of splenocytes from mice immunised with the different Fel d 1 
allergens, only cells from MAT-Fel d 1 immunised mice secreted significant levels of IL-2 
(p<0.05) (Fig. 3a). Immunisation with MAT-Fel d 1 also increased secretion of IFN-γ (Fig. 
3b) as compared to TAT-Fel d 1 (p<0.05) and rFel d 1. In contrast, IL-4 (Fig. 3c) and IL-10 
(Fig. 3d) secretion was found to be stronger upon immunisation with rFel d 1. Stimulation 
of cells from untreated mice did not induced detectable levels of the mentioned cytokines 
(not shown). 
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Figure 3. Cytokine secretion in vitro. Splenocytes from mice immunised with MAT-Fel d 1, TAT- Fel d 1 or 
rFel d 1 were analysed for secretion of IL-2 (a), IFN-γ (b), IL-4 (c) and IL-10 (d) after in vitro re-stimulation 
with 10 µg/ml LoTox Fel d 1. The results show the cytokine concentrations in supernatants after subtraction 
of spontaneous secretion from unstimulated splenocytes as determined by ELISA. Statistical differences are 
indicated when p < 0.05 as analysed by the Kruskal-Wallis test with Dunn’s multiple comparison posttest (n 
=4). 
  
Immunotherapy with modified Fel d 1 enhanced protection against anaphylaxis 
Mice sensitised to cat fur allergen extract had high levels of serum IgE and IgG1, but 
no detectable IgG2a (Fig. 4a; time point zero). Upon desensitisation with three i.l. 
injections of different allergens, MAT-Fel d 1 induced the highest IgG2a levels, followed 
by TAT-Fel d 1, rFel d 1 and cat fur extract. Four weeks after completed immunotherapy, 
mice were challenged with a high-dose of cat fur allergen extract and subsequently 
monitored for anaphylaxis. Mice treated with MAT-Fel d 1 showed stronger protection 
against anaphylaxis than mice treated otherwise (Fig. 4b), however, it was only 
significantly different from the cat fur allergen extract treated group (p<0.05) but not 
compared to rFel d 1 treated group. 
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Figure 4. Murine anaphylaxis model. (a) Cat allergen-specific IgG1 and IgG2a antibodies and total IgE were 
analysed in sera from sensitised mice before SIT (time point 0), as well as 6 and 9 weeks after the first SIT 
injection. The negative control group consisted of naive mice, and the positive control was a group of 
sensitised mice that did not receive SIT. (b) Four weeks after the last SIT injection, mice were challenge with 
20 µg of cat fur allergen extract i.p. and the body temperature drop was measured before and 30 minutes after 
the challenge. Data were analysed by the Kruskal-Wallis test with Dunn’s multiple comparison posttest (* p < 
0.05) (n = 5).  
 
Modified allergens did not induce anaphylaxis in sensitised mice 
To assess the safety of modified recombinant allergens in SIT, their capacity to induce 
anaphylaxis in sensitised mice was measured. After the last of six sensitisation injections 
with cat fur allergen extract, all animals had comparable high levels of Fel d 1 specific 
IgG1 and IgE, whereas IgG2a was not detectable (not shown). Mice were then challenged 
with the different recombinant Fel d 1 allergens or with cat fur allergen extract (Fig. 5). 
Three out five mice challenged with rFel d 1 and five out of five challenged with cat fur 
allergen extract experienced anaphylaxis while none of the mice challenged with MAT-
Fel d 1 or TAT-Fel d 1 showed a notable drop in body temperature.  
 
Figure 5. In vivo safety. Mice were sensitised with cat fur allergen extract and 3 weeks after the last 
injections challenged with the pure extract or the different Fel d 1 proteins. Body temperature was measured 
before and 30 minutes after the challenge. Results are illustrated as means ± SEM (n=5). Differences between 
the three recombinant proteins were analysed by the Kruskal-Wallis test with Dunn’s multiple comparison 
posttest (**p<0.01). 
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Reduced degranulation of human basophils after incubation with MAT-Fel d 1  
Further evaluation of the potential safety of MAT-Fel d 1 in human immunotherapy 
was performed by testing the allergen-induced degranulation of human basophils from cat 
fur allergic patients in CAST-ELISA. While the second lowest concentration of cat fur 
allergen extract or rFel d 1 caused strong basophil degranulation and leukotriene release, a 
100-fold higher concentration of MAT-Fel d 1 allergen was required to induce comparable 
basophil degranulation (Fig. 6). 
 
Figure 6. CAST ELISA assay. Blood from 10 cat allergic patients was used for measuring the leukotriens  
(LT) released after incubation with MAT-Fel d 1 (■), rFel d 1 (▲) or cat fur allergen extract (●) at 4 different 
concentrations. Results are illustrated as means ± SEM and statistical comparison between MAT-Fel d 1 and 
rFel d 1 was analysed by the Mann-Whitney U test (*** p < 0.001, * p < 0.05). 
  Chapter 3 
 90
DISCUSSION  
Although SIT offers medical advantages over symptomatic treatments of IgE mediated 
allergies, merely 3-4% of allergic patients choose to undergo SIT, mainly due to the long 
treatment duration and the frequently associated allergic side effects. For use in SIT it 
would therefore be highly desirable to have allergens that enhance efficacy and at the same 
time reduce allergic side effects, i.e., to render SIT faster and safer. In the present study, 
different modified recombinant Fel d 1 allergens were tested for their therapeutic potential 
in SIT. The allergens were in part modified by fusing them to a protein translocation 
sequence to improve cellular uptake and a truncated invariant chain for targeting to the 
MHC class II pathway of antigen presentation (Crameri et al., 2007).  
SIT aims at regulating allergen-specific immune responses, e.g. to trigger Th1 cells as 
well as neutralising antibody responses. The presence of Th1 cytokines such as IFN-γ 
inhibits the production of IL-4 and thereby prevents the IL-4 mediated IgE-switch of B 
cells. IgE enhances the expression of high affinity IgE receptors (FcεRI) (Kawakami and 
Galli, 2002), hence, allergy is self promoting. Our study revealed that mice immunised with 
MAT-Fel d 1 had higher levels of IFN-γ and lower levels of IL-4 than mice immunised 
with the unmodified Fel d 1 allergen. Furthermore, the enhanced production of Th1 assisted 
antibodies, IgG2a in mice (Johansen et al., 2005c) and IgG1 and IgG4 antibodies in 
humans (Till et al., 2004), has been reported after SIT. In line with this, immunotherapy of 
sensitised mice using MAT-Fel d 1 induced higher IgG2a levels and conferred better 
protection against a challenge with a high dose of the cat fur allergen extract.  
In addition to being more efficient in stimulating Th1 immune responses, our study 
revealed that MAT-Fel d 1 also reduced basophil degranulation and leukotriene release by 
a 100-fold when compared to unmodified Fel d 1 or the cat fur allergen extract. This 
potentially increased safety profile of MAT-Fel d 1 was confirmed in sensitised mice that 
showed no anaphylaxis after a high-dose challenge with MAT-Fel d 1 or TAT-Fel d 1. This 
increased safety of the modified allergens could be explained by a reduced IgE-binding 
capacity. However, while MAT-Fel d 1 indeed showed reduced IgE binding (not shown), 
TAT-Fel d 1 did not. Therefore, the reduced allergic reactivity observed in mice of the 
TAT allergen and maybe also in part of the MAT allergen is rather the result of a more 
rapid cellular uptake (Brooks et al., 2005; Gump and Dowdy, 2007) that prevents the 
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allergen from binding to FcεRI on mast cells and basophils. In conclusion, these results 
demonstrated that MAT- Fel d 1 not only increased SIT efficacy but also safety.  
Over the last ten years, several studies have reported enhanced presentation of antigens 
through the MHC class-II pathway by different strategies that involved the Ii (Bischof et 
al., 2001; Carstens et al., 2000; Kallinteris et al., 2006). For instance, the so called Ii-Key 
peptides, consist of a short fragment of the human Ii (hIi aa77-92 or aa77-80) fused to an 
antigenic peptide (Kallinteris et al., 2006). The Ii-Key binds to an allosteric site of the 
MHC-II molecules on the cell surface and the antigenic peptide binds to the epitope 
binding groove, increasing the loading of MHC class II molecules and, therefore, 
enhancing the immunogenicity of the loaded antigen. The MAT allergens used in our study 
had a longer sequence of the hIi (aa 1-110). This targets the MHC class-II molecules in the 
endoplasmatic reticulum (Crameri et al., 2007) where it occupies the peptide binding 
groove, and thereby avoids interaction with other antigens. The complex formed by the 
MAT-allergen and the MHC class-II molecule is directed through the Golgi to the 
endo/lysosomal compartment where the Ii can be degraded together with the fused allergen. 
Now, the allergenic peptides can be loaded to the MHC class-II molecules and be 
transported to the cell surface (Bonehill et al., 2005). As a result, MAT allergens increase 
the efficiency of allergen presentation, which furthermore result in an increase in the 
effective allergen dose available for stimulation of protective immune responses. Indeed, 
high allergen doses suppress IgE production while low doses are supportive of its 
production (Ruedl et al., 2000), and human immunotherapy with high allergen doses is 
more efficient than using lower allergen doses (Powell et al., 2007). While this strategy in 
theory could be advantageously used for SIT, the risk of allergic adverse events limits the 
possibility of increasing the therapeutic allergen dose and explains the need for a controlled 
dose-escalation during the early phase of SIT. However, the safety profile as well as the 
cell-penetration and MHC-targeting properties of MAT allergens may allow SIT with high 
allergen doses, making such allergens highly attractive in human therapy. 
This study, as well as other studies in mice (Johansen et al., 2005a) and humans 
(manuscript in preparation), also demonstrated that intralymphatic allergen administration 
may strongly improve SIT efficacy and allow lower allergen doses to be used, which again 
would improve safety as compared to subcutaneous SIT. Alternative routes of allergen 
administration, e.g. sublingual (SLIT), oral and intranasal applications (Barbey et al., 2004; 
Bohle et al., 2007; Razafindratsita et al., 2007) have been introduced as a means to improve 
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SIT. However, as most proteins have short half-lives, most of such administered allergens 
are degraded before exerting their immunotherapeutic effects. For this reason, 
intralymphatic injections, in which the allergen is administered directly into a subcutaneous 
lymph node, i.e., to the site of action of the immune system, represent an advantage over 
other administration routes.  
In conclusion, our data demonstrated that the two main problems of current SIT, its 
relatively low efficiency requiring a high number of injections, as well as the risk of 
allergic reactions, could both be improved by using MAT allergens. 
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ABSTRACT 
PURPOSE: Allergen-specific immunotherapy (SIT) requires dozens of subcutaneous 
injections over three to five years in order to control IgE-mediated hypersensitivity, which 
is a T-helper 2 (Th2)-associated pathology. This study investigates the use of poly(lactide-
co-glycolide) (PLGA) microparticles combined with immunostimulatory 
oligodeoxynucleotide (CpG) as well as protamine in SIT.  
METHODS: We prepared microparticle formulations with the major allergen of bee 
venom, phospholipase A2 (PLA2), and analyzed the effect of co-encapsulated or admixed 
CpG in both naïve and bee venom allergic mice.  
RESULTS: Mice immunized with microparticles containing only PLA2 induced weak 
antibody responses. In contrast, the combination with CpG resulted in strong PLA2-
specific antibody responses. The presence of CpG was required for the induction of the 
Th1-associated isotype IgG2a, and the titers of IgG2a in sensitized mice correlated with a 
better protection against an allergen challenge. The effect of CpG was further strengthened 
when protamine was co-encapsulated for complexation of CpG. 
CONCLUSIONS: This study shows that allergen-specific immunotherapy with a PLGA-
based allergen-delivery system in combination with CpG enhanced the induction of 
protective IgG2a immune responses. This may improve SIT compliance and shorten its 
duration. 
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INTRODUCTION 
Approximately 20% of the population in developed countries suffers from IgE-
mediated type-I hypersensitivity. The clinical manifestations of this type of allergy are 
rhino-conjunctivitis, asthma or even life-threatening anaphylactic reactions. These 
symptoms are all initiated by the degranulation of mast cells and basophils when their 
surface-bound IgE molecules are cross-linked through the binding of the allergen. 
Although symptomatic treatments are available, the only treatment with long-lasting effect 
for allergic patients is subcutaneous allergen-specific immunotherapy (SIT). During SIT, 
gradually increasing doses of the allergen are injected subcutaneously. This shifts the 
immune response against the allergen from a predominantly Th2-type response (IgE and 
IL-4) towards a Th1-like immune response (IgG and IFN-γ). The risk of allergic side 
effects is currently a major disadvantage of SIT. This has motivated the study of safer 
allergens such as oligopeptides derived from allergens, or recombinant proteins with 
reduced IgE-binding capacity (Alexander et al., 2002; Kussebi et al., 2005; Larche, 2002). 
A second significant disadvantage of SIT is the high cost with a total of 30-80 injections 
administered over years (Durham et al., 1999). A simplified SIT with a reduced number of 
injections would, therefore, be highly advantageous, as it would improve patient 
compliance and provide socio-economic benefits. The most frequently common adjuvants 
in SIT are aluminum salts, being known to favor Th2 responses (including IgE production). 
Aluminum salts can cause local granuloma formation at the injection site, but otherwise 
have a good safety record in SIT. Nevertheless, many efforts are directed towards the use 
of new adjuvants that favor Th1 responses (Wheeler and Woroniecki, 2001).  
Biodegradable materials such as poly(lactide-co-glycolide) (PLGA) represent a 
potential alternative for controlled delivery of allergens in SIT (Jilek et al., 2004). PLGA 
preparations can deliver proteins over prolonged periods of time and induce protective 
immunity after a single subcutaneous injection (Peyre et al., 2004; Peyre et al., 2003). In 
addition, they may also comprise adjuvants or other immune-regulating compounds, e.g. 
Th1-triggering compounds. 
Major candidate adjuvants that shift the immune responses towards Th1 are derived 
from pathogens. The so-called pathogen-associated molecular patterns (PAMPs) are 
recognized by receptors (Toll-like receptors, TLRs) on antigen presenting cells (APCs) 
(Akira and Sato, 2003). TLR binding may activate nuclear factor-κB, which directs the 
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secretion of cytokines, chemokines and co-stimulatory molecules important for efficient 
Th1 immune responses. Bacterial DNA containing cytosine-guanine rich 
immunostimulatory sequences (CpG) have been recognized to bind to TLR-9 and to trigger 
strong Th1 responses (Krieg, 2002; Krieg et al., 1995). 
In this study, we tested PLGA microparticles in combination with CpG for their use in 
subcutaneous SIT against the major bee venom allergen phospholipase A2 (PLA2). In 
mice, isotype switching to IgG2a strongly depends on Th1 CD4 T-cell help. Therefore, the 
capacity of a vaccine to trigger IgG2a antibodies was used as an important indicator for the 
screening of appropriate formulations. We found that CpG strongly enhanced the immune 
response and was a prerequisite for the induction of IgG2a antibody responses. This effect 
was more pronounced when the CpG was co-encapsulated rather than admixed to PLA2-
containing MP. The best prophylactic and therapeutic immune responses were obtained 
with PLGA preparations that contained both co-encapsulated CpG and protamine. 
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MATERIALS AND METHODS 
Materials 
Purified phospholipase A2 (PLA2) from bee venom was purchased from Sigma-Aldrich 
(Buchs, Switzerland). Bee venom extract from ALK-Abelló was purchased through 
Trimedal (Bruttisellen, Switzerland). Aluminum hydroxide (Alhydrogel 2%) was purchased 
from Brenntag Biosector (Fredrikssund, Denmark), and phosphorothioate-modified CpG 
oligodeoxynucleotide 1668pt (5’-TCC-ATG-ACG-TTC-CCT-GAC-GTT-3’) was 
synthesized by Microsynth (Balgach, Switzerland). We used a 35 kDa poly(lactide-co-
glycolide) (PLGA 50:50) with uncapped end-groups (Resomer RG503H) from Boehringer-
Ingelheim (Ingelheim, Germany). Salmine sulfate from salmon sperm (protamine sulfate 
with four arginine residues at the C-terminus) and poly(vinyl alcohol) (PVA, Mowiol 4-88) 
were obtained from Fluka (Buchs, Switzerland). 
Microparticle preparation 
PLGA microparticles (MP) were made by microextrusion-based w/o/w-solvent 
extraction using a static multilamination type micromixer (Institut für Mikrotechnik Mainz 
GmbH, Mainz, Germany), as previously described (Freitas et al., 2003), with slight 
modifications. Three different formulations were prepared. For one formulation, 2 mg of 
PLA2 were dissolved in 100 µl water and emulsified by ultrasonication with 7 ml PLGA 
dissolved in dichloromethane (5%, w/w). For the others either 4 mg PLA2 or a mixture of 4 
mg PLA2 and 8 mg protamine were dissolved in 1.6 ml water containing 1.6 µmol CpG; 
this aqueous phase was emulsified with 12 ml of a 5% PLGA solution in dichloromethane. 
After extrusion in the micromixer, the suspension of MP was collected in a borosilicate 
glass beaker containing an aqueous solution of 0.5% (w/w) PVA for solvent extraction. The 
particles were gently stirred using a magnetic rod and kept in a laminar air flow for 30 min 
for further solvent removal and hardening of the particles. Finally, the particles were 
collected on a 0.8 µm pore-sized mixed cellulose ester membrane filter (Schleicher & 
Schuell, Dassel, Germany) and dried at 20 mbar and room temperature for 24 h. 
Particle size determination 
Microparticle size distributions were determined by laser diffraction using a 
Mastersizer X (Malvern Instrument, Malvern, UK) after suspending approximately 1 mg of 
  Chapter 4 
 
 
101
dried MP in distilled water or in an aqueous solution of 1% lecithin. The average 
cumulative undersize distributions (D10, D50 and D90) were determined on a volume basis. 
Zeta potential measurements 
The surface charge of the MP was determined by zeta potential measurement using a 
Zetasizer 3000 HSA from Malvern Instrument (Malvern, UK). Duplicates of approximately 
0.2 mg of dried MP were re-suspended in 2 ml of a solution of 1 mM KCl (pH 7.6). 
Alternatively, the MP were re-suspended in 1% lecithin and then diluted with 2 ml of 1 
mM KCl. Mean values of zeta potential were calculated from triplicates of each sample.  
Determination of allergen content and integrity in the microparticles 
The extraction of allergen from the MP for the analysis of its content and integrity was 
undertaken as previously described (Gebrekidan et al., 2000). Triplicates of approx. 7 mg 
particles were dissolved in 0.5 ml chloroform by vortexing for three minutes. PLA2 was 
then extracted from the organic phase by mixing with 0.2 ml Tris-HCl buffer and 
subsequent centrifugation at 3000 rpm for 3 minutes. The PLA2 concentration in the 
aqueous supernatant was analyzed by an ELISA inhibition assay. In detail, 60 µl of the 
Tris-HCl phase containing the extracted PLA2 were mixed in a 96-well plate with 60 µl of 
diluted (1:25) human anti-PLA2 serum in phosphate-buffered saline containing 0.05% 
Tween20 and 2.5% skimmed dry milk (PBSTM). In parallel, two-fold dilutions of PLA2 
were mixed with sensitized serum, and established as a standard for quantification. Positive 
(only serum) and negative (only PBSTM) controls were also included. After 2 hours of 
incubation at 37°C, 100 µl of each sample were transferred to an ELISA plate that was pre-
coated with 5 µg/ml PLA2 at 4°C overnight and subsequently blocked with PBSTM at 
room temperature for 1 hour. The samples were then incubated at 37 °C for 2 hours. 
Subsequently, the plate was washed and incubated with 100 µl of a 1:1000 dilution of 
horseradish peroxidase-conjugated anti-human IgG (BD Biosciences Pharmingen, San 
Diego, CA) at room temperature for 1 hour. The plate was washed and developed with 100 
µl of the enzyme substrate 2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) 
diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogen phosphate. After 30 min, the 
absorption was read at 405 nm. The loading efficiency of PLA2 in the MP was calculated 
relative to the theoretical maximum loading value.  
To assess the integrity of the allergen during MP preparation and storage, PLA2 from 
the various MP formulations was extracted with chloroform (as described above), loaded 
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under reduced conditions on SDS-PAGE and run at 180 V for 50 min. Following 
electrophoresis, the gel was stained with the silver-staining method as previously described 
(Nesterenko et al., 1994). 
In vitro release of PLA2  
Accurately weighed PLA2-loaded MP (20 mg) were dissolved in 3.4 ml PBS 
containing 0.2% BSA and incubated in a shaker at 37°C for 63 days. At different time 
points, the samples were centrifuged at 3500 rpm for 10 minutes. Aliquots of the 
supernatants were analyzed by inhibition ELISA to quantify the released PLA2. The 
dissolution medium was replaced with fresh PBS/BSA after each sampling. 
Immunization of mice 
In a preliminary set of experiments, the dose of PLA2 contained in PLGA MP 
necessary to induce solid immune responses was determined. For dose finding, mice were 
immunized twice at an interval of 28 days with MP formulations (MP-PLA2, MP-PLA2-
CpG-protamine) containing either 1 µg or 5 µg of PLA2, or with 1 µg of PLA2 adsorbed 
on aluminum hydroxide. Blood was collected on days 28, 56 and 84. The sera were frozen 
and kept at -20°C until analyzed by ELISA. 
The immunogenicity of PLA2-containing PLGA formulations was tested in 6-10 week 
old female CBA/J mice. Mice were primed with 1 µg PLA2 entrapped in the different 
PLGA formulations (Table 1). Prior to injection, the MP were re-suspended using a 1% 
aqueous lecithin solution (Epikuron 200, Degussa, Hamburg, Germany) as a wetting agent 
and injection vehicle. For the MP-PLA2 + CpG formulation, 3.1 nmol CpG per dose was 
admixed to the MP-PLA2 prior to injection. As a reference, one group of mice received the 
same amount of PLA2 adsorbed for 1 hour to 0.9 mg aluminum hydroxide (PLA2 + 
aluminum hydroxide). Approximately 95% of the PLA2 was adsorbed to aluminum 
hydroxide (data not shown). All mice were boosted with the same regime after 28 days. 
Serum was prepared from clotted blood taken on days 28, 55 and 84 and frozen at -20°C 
until analyzed by ELISA. 
To evaluate the therapeutic potential of PLA2-containing preparations in allergic mice, 
the animals were sensitized by 6 weekly intraperitoneal injections of 0.3 µg bee venom 
allergen extract adsorbed on 1 mg aluminum hydroxide in PBS. Three weeks later (time 
point 0), desensitization (SIT) was initiated with different MP preparations containing 1 µg 
PLA2 or, alternatively, 5 µg PLA2 adsorbed on aluminum hydroxide. The treatment was 
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repeated after 28 days with the same dose and, after 111 days, with 5 µg PLA2 in all 
formulations (MP and aluminum hydroxide). Blood was taken on days 0, 28, 55, 111 and 
139 after the first SIT injection. The sera were frozen and kept at -20°C until analyzed by 
ELISA. For induction of anaphylactic responses, immunized mice were challenged 
intraperitoneally with 15 µg PLA2 in saline, and the rectal temperature was measured with 
a calibrated digital thermometer before and 30 min after the challenge.  
All animal experiments were performed according to the guidelines of the veterinary 
authorities of the Canton of Zurich. 
Antibody determination by enzyme-linked immunosorbent assay 
For detection of PLA2 antibodies, microtitre 96-well plates (Nunc Maxisorb) were 
coated with 100 µL of 5 µg/mL PLA2 in buffered carbonate (pH 9.4) and incubated at 4°C 
overnight. Plates were washed with PBS-0.05% Tween 20 (PBST) and blocked with 150 µl 
of 2.5% PBSTM for 1 hour. After washing, serial dilutions of individual sera in 100 µL 
PBSTM were incubated in the plates for 2 hours. Subsequently, the plates were washed and 
incubated with 1 µg/mL biotinylated goat anti-mouse IgG1 or IgG2a in 100 µL PBSTM for 
2 hours. After washing and incubation with 100 µL of a 1:1000 dilution of streptavidin-
conjugated horse-radish peroxidase for 1 hour, the plates were washed and developed with 
100 µL enzyme substrate 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogen phosphate. After 20 min, the 
endpoint absorption was measured at 405 nm. For detection of specific IgE antibodies, 
plates were coated with 2 µg/ml of anti-mouse IgE capture antibody. As secondary reagent 
for binding to mouse serum, an in-house biotinylated PLA2 was used at 3 µg/ml. Unless 
specified, all antibodies were from BD Biosciences Pharmingen, and all incubations were 
done at room temperature. 
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RESULTS 
Microparticle characterization  
Three different PLGA formulations were prepared by a recently developed 
microextrusion based process (Fischer et al., 2006; Freitas et al., 2003). The size of the 
particles increased slightly depending on the number of encapsulated components (Table 
1). While 50% of the MP-PLA2-CpG-protamine particles were smaller than 8.2 µm, half 
the MP-PLA2 particles were smaller than a 4.41 µm. The 90% cumulative undersize values 
were comparable for all tested formulations, i.e., 20.1 µm (MP-PLA2-CpG) to 26.3 µm 
(MP-PLA2-CpG-protamine). The re-suspension of the particles in 1% lecithin resulted in 
an apparent increase in size of the MP-PLA2-CpG formulation but not for the other 
formulations (not shown).  
Table 1. Zeta potential and PLA2 content of the tested microparticle (MP) preparations.  
 Size distribution 
(µm) 
D10 / D50 / D90 
Zeta potential (mV)  
w/o or w lecithin 
PLA2 
content 
(µg/mg MP) 
PLA2 loading 
efficiency (%) 
MP-PLA2 1.2 / 4.4 / 24.9 -7.3 ± 0.3 -12.3 ± 1.6 0.84 29 
MP-PLA2 + 
CpG 
1.2 / 4.4 / 24.9 -7.3 ± 0.5  -9.7 ± 0.5 0.84 29 
MP-PLA2-CpG 1.3 / 5.6 / 20.1 -9.1 ± 1.8  -12.5 ± 0.9 1.55 33 
MP-PLA2-
CpG-protamine 
2.4 / 8.2 / 26.3 -9.6 ± 1.8  -13.7 ± 1.6 0.95 22 
The MP-PLA2 + CpG corresponds to the MP-PLA2 preparation, but contains CpG that was admixed prior to 
injection; therefore, the PLA2 content of the two preparations are the same. The particle size distribution is 
indicated as D10, D50 and D90 cumulative undersizes. 
The zeta potential of all MP formulations was negative and changed only marginally 
upon admixture of CpG (from -7.5 mV for MP-PLA2 to -7.3 mV for MP-PLA2 + CpG), or 
upon co-encapsulation of CpG (-9.5 mV for MP-PLA2-CpG), or else upon co-
encapsulation of both CpG and protamine (-9.6 mV for MP-PLA2-CpG-protamine) (Table 
1). When the particles were re-suspended in lecithin, the zeta potentials decreased 
significantly in all formulations (p<0.01; un-paired, two-sided Student’s t-test).  
The experimentally determined PLA2 content in the MP ranged from 0.84 µg/mg (MP-
PLA2) to 1.55 µg/mg (MP-PLA2-CpG) (Table 1). The corresponding microencapsulation 
efficiencies were in the range of 22% to 33%.  
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The analysis of extracted PLA2 from the different MP formulations by SDS-PAGE 
produced a unique band for PLA2 at 16 kDa (Fig. 1), which does not suggest any cleavage 
of the allergen during preparation and storage (6-12 months) of the MP. Furthermore, 
extracted PLA2 maintained its antigenicity as confirmed by inhibition ELISA with a 
polyclonal human antiserum (data not shown), suggesting that the protein structure 
remained intact during the MP preparation and storage. 
 
 
Figure 1. Silver-stained SDS-PAGE of PLA2 extracted from the different microparticle formulations. 
Seeblue Plus was used as a marker. Lane 1 corresponded to MP-PLA2, lane 2 to MP-PLA2-CpG, lane 3 to 
MP-PLA2-CpG-protamine and the last lane (4) was loaded with 1 µg of purified PLA2 as a positive control. 
For all the other lanes, maximal loading volumes were used. 
 
The in vitro release of PLA2 from all formulations was triphasic and followed the same 
pattern (Fig. 2). An initial burst release during the first 24 hours was followed by a dormant 
period over two weeks and a second release phase lasting more than seven weeks. While 
the release of PLA2 from the protamine-containing formulation was complete over this 
time period, the release from the protamine- and CpG-free formulation (MP-PLA2) 
reached only 63%. 
 
Figure 2. Allergen in vitro release profile of the different MP formulations. PLA2 release at different time 
points as measured by inhibition ELISA and expressed in microgram per dose of MP used for the experiment 
and total release in percentage. MP-PLA2 (■), MP-PLA2-CpG (▼) and MP-PLA2-CpG-protamine (●). 
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Immunogenicity 
We first determined the dose of microencapsulated PLA2 required to induce a specific 
immune response in mice after subcutaneous administration of two different PLGA MP 
preparations. Mice were immunized with 1 µg or 5 µg of microencapsulated PLA2 in MP-
PLA2 or MP-PLA2-CpG-protamine and boosted 28 days later with the same doses. As a 
control, one group of mice was primed and boosted with 1 µg PLA2 adsorbed on aluminum 
hydroxide. As illustrated in Figure 3, 5 µg PLA2 in MS-PLA2 induced high levels of IgG1 
while the 1 µg PLA2 dose induced only weak IgG1 responses and no detectable IgG2a 
antibodies. The CpG- and protamine-containing particles were strongly immunogenic for 
both IgG1 and IgG2a induction both at 1 µg and 5 µg PLA2, and a single administration 
was sufficient for seroconversion in the latter group. Aluminum-adsorbed PLA2 induced 
only IgG1 antibodies and boosting was required.  
 
Figure 3. Dose-dependant immunogenicity of PLA2-containing microparticles. Mice (n=3) were immunized 
on days 0 and 28 with 1 µg (empty symbols) or 5 µg (filled symbols) of PLA2 contained in MP-PLA2 
(triangles), MP-PLA2-CpG-protamine (circles), or with 1 µg of PLA2 adsorbed on Al(OH)3 (×). The sera 
were obtained at days 28, 56 and 84 and analyzed by ELISA for anti-PLA2 IgG2a (a) and IgG1 (b). The 
absorbances at 1/160 serum dilution were chosen as representative for each time point. 
 
Based on these results, we tested the immunogenicity of four different PLGA MP 
preparations containing 1 µg of PLA2 (Table 1). Mice received two injections 28 days 
apart, and the PLA2-specific antibodies were measured 28, 55 and 84 days after the first 
injection. In line with the results above, a single administration of the CpG-free formulation 
(MP-PLA2) induced little or no detectable anti-PLA2 antibodies by day 28 (Figure 4). At 
this time point, only the formulation MP-PLA2-CpG-protamine induced some IgG1, but no 
IgG2a antibodies. A second injection on day 28 did not notably increase the antibody titers 
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of mice that had received MP-PLA2, unless CpG was admixed prior to injection (MP-
PLA2 + CpG). The co-encapsulation of CpG (MP-PLA2-CpG) further increased this 
response, which was additionally enhanced when both CpG and protamine were co-
encapsulated (MP-PLA2-CpG-protamine). Maximum antibody titers for both IgG 
subclasses were observed one month after the second injection (day 55), after which time 
the antibody levels slightly decreased or remained stable during the next month (day 84). 
The IgG2a levels induced by the two MP preparations with encapsulated CpG (MP-PLA2-
CpG and MP-PLA2-CpG-protamine), but not with admixed CpG (MP-PLA2 + CpG), were 
significantly higher than those induced by PLA2 adsorbed on aluminum hydroxide (p<0.05 
for the MP-PLA2-CpG and p<0.001 for the MP-PLA2-CpG-protamine, as analyzed by a 
two-way ANOVA with Bonferroni posttest). Also, the quality of the total immune response 
was different between the immunogenic PLGA preparations and the aluminum adsorbed 
control vaccine. The latter induced an IgG1 (Th2) polarized antibody response, while the 
particles shifted the response towards an IgG2a (Th1), as evident from the IgG2a-to-IgG1 
ratios (Figure 4c). Neither the PLGA preparations nor the control group (aluminum 
hydroxide) induced detectable PLA2-specific IgE antibodies (data not shown).  
 
Figure 4. Isotype profiles of anti-PLA2 serum antibodies. CBA/J mice were vaccinated on days 0 and 28 
with 1 µg PLA2 in different microparticle formulations, as indicated, or adsorbed on aluminum hydroxide as 
reference (n=4). Blood was collected at days 28, 55 and 84 and the sera analyzed by ELISA for anti-PLA2 
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IgG2a (a) and IgG1 (b). Ratio of IgG2a to IgG1 was calculated at 1/800 serum dilution and only values above 
seroconversion (absorbance higher or equal than that of a negative serum plus three standard deviations) are 
plotted (c). Data were analyzed by a two-way ANOVA with Bonferroni posttest. Significant differences are 
indicated as compared to the control group (*** p<0.001; ** p<0.01; * p<0.05).  
 
Allergen-specific immunotherapy 
To evaluate the therapeutic potential of the different MP formulations, we used a 
murine anaphylaxis model. Mice were sensitized by six weekly intraperitoneal injections of 
bee venom allergen extract adsorbed on aluminum hydroxide. Three weeks after the last 
sensitization injection, SIT was initiated by subcutaneous injections with different PLGA 
formulations containing 1 µg PLA2 or with 5 µg PLA2 adsorbed on aluminum hydroxide 
(Fig. 5).  
 
Figure 5. Schematic illustration of the therapeutic immunization protocol. Black arrows represent injections 
and grey arrows represent bleedings. 
 
As evident from Figure 6a, two injections with 1 µg of microencapsulated PLA2 were 
not sufficient to induce detectable titers of PLA2-specific IgG2a antibodies in the 
sensitized mice. Therefore, the animals were boosted at day 111 after the first SIT injection 
with the same MP preparations, but at the higher dose of 5 µg PLA2. This increased the 
levels of allergen-specific IgG2a significantly compared to the pre-boosting titers. The two 
formulations with encapsulated CpG induced significantly stronger (p<0.05, as analyzed by 
a two-way ANOVA with Bonferroni posttest) IgG2a responses than those induced by the 
control vaccine with aluminum hydroxide. Finally, to assess the functional efficacy of the 
different treatments, mice were challenged with a high dose of PLA2, and their body 
temperature monitored before and after the challenge. Mice treated with MP containing 
CpG had the smallest body temperature drop (Fig. 6b), being significantly lower than that 
observed in the untreated control group (p<0.05 for MP-PLA2-CpG and p<0.01 for MP-
PLA2-CpG-protamine, as analyzed by a one-way ANOVA with Dunnet’s Multiple 
comparison test). In fact, IgG2a responses correlated with protection against anaphylaxis 
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(p=0.02, correlation analyzed by the Pearson test). The higher the IgG2a titers, the lower 
the temperature drop (Fig. 6c). 
The levels of bee-venom specific of IgE and IgG1 increased similarly for all groups 
during the sensitization period and remained unchanged during SIT. For all groups, PLA2-
specific IgG1 increased comparably during both sensitization and SIT (data not shown). 
 
Figure 6. Therapeutic potential of PLA2-containing microparticles. (a) Sensitized mice as described in the 
Materials and Method section were therapeutically vaccinated with MP-PLA2 (□), MP-PLA2 + CpG (∆), 
MP-PLA2-CpG (▼), MP-PLA2-CpG-protamine (▲), PLA2 adsorbed on Al(OH)3 (●), or left untreated (■). 
IgG2a titers were defined as the inverse of the highest dilution reaching an absorbance equal or higher than 
that of a negative serum plus three standard deviations and expressed as geometric means ± standard error 
(n=5). Similar levels of IgG1 and IgE were seen for all groups treated (not shown). (b) Induction of 
anaphylaxis responses against PLA2 in desensitized mice. After desensitization, the mice were challenged 
with 15 µg of purified PLA2, and the body temperature was measured before and 30 minutes after the 
challenge. Values are expressed as body temperature difference before and after. Significant differences are 
indicated as compare to the untreated group (** p<0.01; * p<0.05). (c) Correlation between the level of 
protective antibodies and body temperature change. The IgG2a absorbance from the last time point was 
plotted versus the body temperature change in challenged mice. The correlation was analyzed by the Pearson 
test, which assumes that the data is sampled from a Gaussian population, with a 95% confidence interval. 
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DISCUSSION 
Allergen-specific immunotherapy (SIT) aims to shift the balance between Th2 and Th1 
responses in favor of the latter. The consequences are an increase in Th1-related antibodies 
(IgG4 in humans, IgG2a in mice) and cytokines (IFN-γ) (Durham et al., 1996; Gehlhar et 
al., 1999), a reduction in Th2-associated IgE and IL-4 (Secrist et al., 1993), and an increase 
in allergen-specific suppressive activity through regulatory CD25-positive CD4 T cells and 
IL-10 (Nouri-Aria et al., 2004; Till et al., 2004). However, current SIT is costly and 
requires years of allergen injections. As the allergen dose cannot be increased due to 
allergic side effects, concepts to enhance the efficacy of SIT have focused on creating 
recombinant allergens with less allergic side effect or on the developing of new adjuvants 
and delivery systems. So far, only adjuvants based on aluminum and calcium salts have 
been approved for SIT. Both compounds preferentially stimulate Th2-polarized antibody 
responses (Bousquet et al., 1998), but T-cell responses are poor.  
Biodegradable and biocompatible polymeric MP are particularly interesting candidates 
for allergy vaccines, because they release proteins over prolonged periods of time (Ying 
Men et al., 1996) and, thereby, reduce the need for frequent booster injections. Since 
entrapped allergen would be less accessible for binding IgE on the surface of mast cells and 
basophils, the encapsulation of allergens may also protect the allergic patient from 
undesired allergic side effects. Due to their particulate nature and small size, MP also have 
intrinsic adjuvant properties and may be combined with immunostimulatory agents to 
trigger distinct pathways of immunological reactions.  
Oligodeoxynucleotides rich in cytosine-guanine immunostimulatory sequences (CpG) 
are a prototype of Th1 response inducers. CpG stimulates TLR9 on APCs (Hemmi et al., 
2000). It has been shown that CpG can restore imbalanced Th2-Th1 responses in allergic 
mice (Banerjee et al., 2004; Johansen et al., 2005a), and that the conjugation of a ragweed 
allergen to CpG improved the therapeutic efficacy in patients with allergic rhinitis 
(Creticos et al., 2006).  
In the present study, we combined CpG with allergen-containing PLGA MP and 
evaluated the immunogenicity and therapeutic potential of the formulations in a murine 
model of allergy. The results suggested that co-encapsulation of allergen and CpG in 
PLGA MP can have important benefits for application in SIT. CpG lowered the dose-
threshold for induction of allergen-specific immune responses. This paralleled a study that 
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showed that PLGA MP containing a streptococcus antigen and CpG elicited significantly 
higher antigen-specific antibody responses when compared with the same vaccine without 
CpG (Hunter et al., 2001). Moreover, only CpG-containing preparations induced IgG2a 
antibodies, suggesting that a potent allergy vaccine based on PLGA MP should also contain 
CpG or an equivalent Th1-triggering adjuvant. The therapeutic model confirmed this 
finding, by showing that CpG-containing MP preparations protected mice against induced 
anaphylaxis better than CpG-free preparations. 
Despite this clear adjuvant effect of CpG, oligodeoxynucleotides have relatively short 
half-life in vivo due to degradation by nucleases (Agrawal et al., 1995; Farman and 
Kornbrust, 2003). For in vivo use, therefore, they have been stabilized by 
phosphorothioate-modification of the oligodeoxynucleotide backbone (Agrawal et al., 
1995; Sester et al., 2000). Alternatively, CpG has been conjugated to stabilizing 
compounds (Lee et al., 2000; Park et al., 2001) or packaged into virus-like particles (Storni 
et al., 2004). For the same purpose, we tested whether the PLGA MP-based allergy vaccine 
could be further improved by adding protamine to the formulation, as a putative stabilizer 
for DNA. The experiments revealed that the immunogenicity of the vaccine was indeed 
further enhanced when protamine was co-encapsulated. The induction of both IgG1 and 
IgG2a isotypes increased, with a slightly stronger increase of the latter isotype. This 
resulted in better protection against anaphylaxis, as compared to all other PLA2 vaccine 
preparations tested.  
Protamine is a cationic polypeptide that is known to stabilize DNA in the haploid phase 
of spermatogenesis. Pharmaceutically, it has been used to preserve plasmid DNA for gene 
transfer (Li and Huang, 1997) and to avoid degradation of oligodeoxynucleotides 
(Gonzalez Ferreiro et al., 2003). Besides direct stabilization of CpG, the improved 
performance of the protamine-containing formulations could also be a secondary result of 
more efficient encapsulation of CpG due to complexation with protamine. Indeed, CpG 
adsorption was found to be stronger on protamine-containing particles than on protamine-
free particles and the release of CpG was strongly sustained with the former particles (S. 
Fischer, unpublished data). Moreover, due to the neutralization of the negative charges on 
CpG by the positive protamine as well as the increased size of the protamine-CpG 
complex, the complex is expected to have a higher affinity for the polymer matrix than 
CpG alone. This should allow a more delayed release of the CpG, which again would allow 
CpG and the allergen to reach the same APCs. Such a synchronized delivery of danger 
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signals (adjuvant; so-called signal 0 and 2) and allergen (so-called signal 1) is one 
important criterion for optimal stimulation of long-lasting immune responses (Schijns, 
2000). The importance of such synchronized allergen and CpG delivery was further 
underlined by the fact that admixed CpG, released by a faster kinetics than the encapsulated 
allergen, induced weaker antibody responses and less protection than co-encapsulated 
allergen and CpG. Experiments with MP formulations that contained co-encapsulated 
PLA2 and protamine, but no CpG, performed similarly to the MP-PLA2 formulation 
(results not shown). This implies that co-encapsulated protamine exerted its effect through 
stabilization and improved encapsulation of CpG and not due to a direct immune regulatory 
or stimulatory effect. 
One of the major concerns about encapsulation of therapeutic proteins and antigens is 
the risk of degradation or structural changes during the process. This has so far limited the 
clinical use of MP. In our study, the encapsulation of PLA2 did not seem to affect its 
integrity or immunogenicity. Nonetheless, some disruption of the molecule may not be as 
damaging for allergens as it may for other proteins. In fact, many of the new approaches in 
allergy treatment use modified allergens with low IgE binding capacity, e.g., recombinant 
proteins (Crameri and Rhyner, 2006; Wild et al., 2007), chemically cross-linked (Bousquet 
et al., 1990) or heat-denaturated allergens (Johansen et al., 2005b; Kim et al., 2002).  
To the best of our knowledge, this is the first report where the potential of PLGA MP 
with co-encapsulated allergen and CpG has been studied in vivo for use in allergen-specific 
immunotherapy. The preparations were strongly immunogenic in mice and the Th1-
triggering effect of CpG was further improved by co-encapsulation of protamine. 
Importantly, this correlated with a better protection against anaphylaxis in bee venom 
allergic mice. Therefore, due to the increased efficacy and the reduced risk of allergic side 
effects, CpG- and allergen-containing PLGA MP represent a most attractive strategy for 
improving the conventional long-lasting and costly SIT. 
 
 
 
 
  Chapter 4 
 
 
113
Acknowledgements 
The authors thank Mrs. María J. Pena Rodríguez for help with ELISA measurements, 
Mrs. Nathalie Schlegel and Dr. Nicole Graf for English editions, and Prof. Adriano Aguzzi 
for helpful discussions. 
 
Author contributions 
This paper is the result of a fruitful collaboration with the Institute of Drug Formulation 
and Delivery, from Pharmaceutical Sciences, ETH Zurich.  
Together with Stefan Fischer, I prepared the different microparticle formulation at the 
ETH. I performed all animal experiment and analyzed the data. After the paper got 
reviewed, Noémi Csaba helped me to further characterize the microparticles in vitro.  
Pål Johansen took part in the experimental design of the project and guided me through 
the writing of the manuscript. Bruno Gander and Thomas Kündig helped designing the 
experiments and corrected the manuscript. Hans Peter Merkle revised the manuscript. 
 
 
  Chapter 4 
 
 
114
REFERENCES 
Agrawal, S., Temsamani, J., Galbraith, W. and Tang, J. (1995) Pharmacokinetics of 
antisense oligonucleotides. Clin Pharmacokinet, 28, 7-16. 
Akira, S. and Sato, S. (2003) Toll-like receptors and their signaling mechanisms. Scand J 
Infect Dis, 35, 555-562. 
Alexander, C., Kay, A.B. and Larche, M. (2002) Peptide-based vaccines in the treatment of 
specific allergy. Curr Drug Targets Inflamm Allergy, 1, 353-361. 
Banerjee, B., Kelly, K.J., Fink, J.N., Henderson, J.D., Jr., Bansal, N.K. and Kurup, V.P. 
(2004) Modulation of airway inflammation by immunostimulatory CpG 
oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect Immun, 72, 
6087-6094. 
Bousquet, J., Hejjaoui, A., Soussana, M. and Michel, F.B. (1990) Double-blind, placebo-
controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of 
the safety and efficacy of two dosages of a high-molecular-weight allergoid. J 
Allergy Clin Immunol, 85, 490-497. 
Bousquet, J., Lockey, R. and Malling, H.J. (1998) Allergen immunotherapy: therapeutic 
vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol, 102, 
558-562. 
Crameri, R. and Rhyner, C. (2006) Novel vaccines and adjuvants for allergen-specific 
immunotherapy. Current Opinion in Immunology, 18, 761-768. 
Creticos, P.S., Schroeder, J.T., Hamilton, R.G., Balcer-Whaley, S.L., Khattignavong, A.P., 
Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J.J., Broide, D. and the 
Immune Tolerance Network, G. (2006) Immunotherapy with a Ragweed-Toll-Like 
Receptor 9 Agonist Vaccine for Allergic Rhinitis. N Engl J Med, 355, 1445-1455. 
Durham, S.R., Walker, S.M., Varga, E.M., Jacobson, M.R., O'Brien, F., Noble, W., Till, 
S.J., Hamid, Q.A. and Nouri-Aria, K.T. (1999) Long-term clinical efficacy of grass-
pollen immunotherapy. N Engl J Med, 341, 468-475. 
Durham, S.R., Ying, S., Varney, V.A., Jacobson, M.R., Sudderick, R.M., Mackay, I.S., 
Kay, A.B. and Hamid, Q.A. (1996) Grass pollen immunotherapy inhibits allergen-
induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa 
and increases the number of cells expressing messenger RNA for interferon-
gamma. J Allergy Clin Immunol, 97, 1356-1365. 
Farman, C.A. and Kornbrust, D.J. (2003) Oligodeoxynucleotide studies in primates: 
antisense and immune stimulatory indications. Toxicol Pathol, 31 Suppl, 119-122. 
Fischer, S., Foerg, C., Ellenberger, S., Merkle, H.P. and Gander, B. (2006) One-step 
preparation of polyelectrolyte-coated PLGA microparticles and their 
functionalization with model ligands. Journal of Controlled Release, 111, 135. 
Freitas, S., Walz, A., Merkle, H.P. and Gander, B. (2003) Solvent extraction employing a 
static micromixer: a simple, robust and versatile technology for the 
microencapsulation of proteins. J Microencapsul, 20, 67-85. 
Gebrekidan, S., Woo, B.H. and DeLuca, P.P. (2000) Formulation and in vitro transfection 
efficiency of poly (D, L-lactide-co-glycolide) microspheres containing plasmid 
DNA for gene delivery. AAPS PharmSciTech, 1, E28. 
Gehlhar, K., Schlaak, M., Becker, W. and Bufe, A. (1999) Monitoring allergen 
immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to 
IgG1 correlates with clinical outcome. Clin Exp Allergy, 29, 497-506. 
Gonzalez Ferreiro, M., Crooke, R.M., Tillman, L., Hardee, G. and Bodmeier, R. (2003) 
Stability of polycationic complexes of an antisense oligonucleotide in rat small 
  Chapter 4 
 
 
115
intestine homogenates. European Journal of Pharmaceutics and Biopharmaceutics, 
55, 19. 
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., 
Hoshino, K., Wagner, H., Takeda, K. and Akira, S. (2000) A Toll-like receptor 
recognizes bacterial DNA. Nature, 408, 740. 
Hunter, S.K., Andracki, M.E. and Krieg, A.M. (2001) Biodegradable microspheres 
containing group B Streptococcus vaccine: Immune response in mice. American 
Journal of Obstetrics and Gynecology, 185, 1174. 
Jilek, S., Walter, E., Merkle, H.P. and Corthesy, B. (2004) Modulation of allergic responses 
in mice by using biodegradable poly(lactide-co-glycolide) microspheres. J Allergy 
Clin Immunol, 114, 943-950. 
Johansen, P., Senti, G., Martinez Gomez, J.M., Storni, T., von Beust, B.R., Wuthrich, B., 
Bot, A. and Kundig, T.M. (2005a) Toll-like receptor ligands as adjuvants in 
allergen-specific immunotherapy. Clin Exp Allergy, 35, 1591-1598. 
Johansen, P., Senti, G., Martinez Gomez, J.M., Wuthrich, B., Bot, A. and Kundig, T.M. 
(2005b) Heat denaturation, a simple method to improve the immunotherapeutic 
potential of allergens. Eur J Immunol, 35, 3591-3598. 
Kim, M.J., Lee, J.W., Yook, H.S., Lee, S.Y., Kim, M.C. and Byun, M.W. (2002) Changes 
in the antigenic and immunoglobulin E-binding properties of hen's egg albumin 
with the combination of heat and gamma irradiation treatment. J Food Prot, 65, 
1192-1195. 
Krieg, A.M. (2002) CpG motifs in bacterial DNA and their immune effects Annual Review 
of Immunology, 20, 709-760. 
Krieg, A.M., Yi, A.-K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., 
Koretzky, G.A. and Klinman, D.M. (1995) CpG motifs in bacterial DNA trigger 
direct B-cell activation. Nature, 374, 546. 
Kussebi, F., Karamloo, F., Rhyner, C., Schmid-Grendelmeier, P., Salagianni, M., 
Mannhart, C., Akdis, M., Soldatova, L., Markovic-Housley, Z., Von Beust, B.R., 
Kundig, T., Kemeny, D.M., Blaser, K., Crameri, R. and Akdis, C.A. (2005) A 
major allergen gene-fusion protein for potential usage in allergen-specific 
immunotherapy. J Allergy Clin Immunol, 115, 323-329. 
Larche, M. (2002) Anti-T-cell strategies in the treatment of allergic disease. Allergy, 57 
Suppl 72, 20-23. 
Lee, S.W., Song, M.K., Baek, K.H., Park, Y., Kim, J.K., Lee, C.H., Cheong, H.K., Cheong, 
C. and Sung, Y.C. (2000) Effects of a hexameric deoxyriboguanosine run 
conjugation into CpG oligodeoxynucleotides on their immunostimulatory 
potentials. J Immunol, 165, 3631-3639. 
Li, S. and Huang, L. (1997) In vivo gene transfer via intravenous administration of cationic 
lipid-protamine-DNA (LPD) complexes. Gene Therapy, 4, 891. 
Nesterenko, M.V., Tilley, M. and Upton, S.J. (1994) A simple modification of Blum's 
silver stain method allows for 30 minute detection of proteins in polyacrylamide 
gels. J Biochem Biophys Methods, 28, 239-242. 
Nouri-Aria, K.T., Wachholz, P.A., Francis, J.N., Jacobson, M.R., Walker, S.M., Wilcock, 
L.K., Staple, S.Q., Aalberse, R.C., Till, S.J. and Durham, S.R. (2004) Grass pollen 
immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG 
activity. J Immunol, 172, 3252-3259. 
Park, Y., Chang, Y.S., Lee, S.W., Cho, S.Y., Kim, Y.K., Min, K.U., Kim, Y.Y., Cho, S.H. 
and Sung, Y.C. (2001) The enhanced effect of a hexameric deoxyriboguanosine run 
conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J 
Allergy Clin Immunol, 108, 570-576. 
  Chapter 4 
 
 
116
Peyre, M., Fleck, R., Hockley, D., Gander, B. and Sesardic, D. (2004) In vivo uptake of an 
experimental microencapsulated diphtheria vaccine following sub-cutaneous 
immunisation. Vaccine, 22, 2430-2437. 
Peyre, M., Sesardic, D., Merkle, H.P., Gander, B. and Johansen, P. (2003) An experimental 
divalent vaccine based on biodegradable microspheres induces protective immunity 
against tetanus and diphtheria. J Pharm Sci, 92, 957-966. 
Schijns, V.E. (2000) Immunological concepts of vaccine adjuvant activity. Curr Opin 
Immunol, 12, 456-463. 
Secrist, H., Chelen, C.J., Wen, Y., Marshall, J.D. and Umetsu, D.T. (1993) Allergen 
immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic 
individuals. J Exp Med, 178, 2123-2130. 
Sester, D.P., Naik, S., Beasley, S.J., Hume, D.A. and Stacey, K.J. (2000) Phosphorothioate 
backbone modification modulates macrophage activation by CpG DNA. J Immunol, 
165, 4165-4173. 
Storni, T., Ruedl, C., Schwarz, K., Schwendener, R.A., Renner, W.A. and Bachmann, M.F. 
(2004) Nonmethylated CG motifs packaged into virus-like particles induce 
protective cytotoxic T cell responses in the absence of systemic side effects. J 
Immunol, 172, 1777-1785. 
Till, S.J., Francis, J.N., Nouri-Aria, K. and Durham, S.R. (2004) Mechanisms of 
immunotherapy. J Allergy Clin Immunol, 113, 1025-1034; quiz 1035. 
Wheeler, A.W. and Woroniecki, S.R. (2001) Immunological adjuvants in allergy vaccines: 
Past, present and future. Allergol Int, 50, 295-301. 
Wild, C., Wallner, M., Hufnagl, K., Fuchs, H., Hoffmann-Sommergruber, K., Breiteneder, 
H., Scheiner, O., Ferreira, F. and Wiedermann, U. (2007) A recombinant allergen 
chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. 
Allergy, 62, 33-41. 
Ying Men, Gander, B., Merkle, H.P. and Corradin, G. (1996) Induction of sustained and 
elevated immune responses to weakly immunogenic synthetic malarial peptides by 
encapsulation in biodegradable polymer microspheres. Vaccine, 14, 1442-1450. 
 
 
  Chapter 5 
 
 
117
 
 
 
 
CHAPTER 5 
 
 
 
 
 
 
 
The coating of PLGA microparticles with protamine 
enhances their immunological performance through 
facilitated phagocytosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 5 
 
 
118
 
The coating of PLGA microparticles with protamine 
enhances their immunological performance through 
facilitated phagocytosis 
 
Julia M. Martínez Gómez1, Anke Sichelstiel1, Noémi Csaba2, Stefan Fischer2, Thomas 
M. Kündig1, Bruno Gander2, and Pål Johansen1 
 
1Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital 
Zurich, Zurich, Switzerland 
2Drug Formulation and Delivery, Institute of Pharmaceutical Sciences, ETH Zurich, 8093 
Zurich, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J. Controlled release (accepted for publication) 
 
  Chapter 5 
 
 
119
ABSTRACT 
Surface modifications of poly (lactide-co-glycolide) microparticles with different 
polycationic electrolytes have mainly been studied for conjugation to antigens and/or 
adjuvants. However, the in vivo immunological effects of using surface charged particles 
have not been address yet. In this study, microparticles were coated or not with protamine, 
a cationic and arginine-rich electrolyte that confers microparticles with a positively surface 
charge. We then evaluated the potential of protamine-coatings to assist the induction of 
immune responses in mice. Interestingly, enhanced antibodies and T-cell responses were 
observed in mice treated with the coated particles. In vitro studies suggested that the 
improved immunological performance was mediated by an increased uptake. Indeed, 
protamine-coated particles that carried a GFP-plasmid were even internalized into non-
phagocytic cells and caused their transfection. These results open the way for further 
research into a novel technology that combines the use protamine for facilitated cell 
penetration and that of biodegradable microparticles for prolonged antigen or drug release. 
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INTRODUCTION  
Polymeric biodegradable microparticles have been widely studied for a broad variety of 
pharmaceutical and biomedical applications (Johansen et al., 2007; Mundargi et al., 2007; 
Varde and Pack, 2004). Commonly used poly(lactide-co-glycolide) (PLGA) types are 
available in medical grade and are approved for use in humans, which makes them 
attractive for developing new drug and antigen delivery systems (Johansen et al., 2000; 
Langer, 1990; Putney and Burke, 1998). With a size range similar to that of 
microorganisms, polymeric particles can be easily taken up by antigen presenting cells 
(APCs) (Peyre et al., 2004b), a process that enables potent cellular as well as humoral 
immune responses (Ataman-Onal et al., 2006; Johansen et al., 1999; Men et al., 1995; Peter 
et al., 2001; Peyre et al., 2004a). 
Physico-chemical properties such as the molecular weight and monomer composition 
of the polymer, and the size and surface charge of the microparticles determine the antigen 
release rate (Peyre et al., 2004a) and may also affect the type of immune response elicited 
by the delivery system (Espuelas S., 2005; Johansen et al., 2000). To add further flexibility 
and control of antigen and adjuvant delivery, the surface properties of PLGA microparticles 
have been modified (Fischer et al., 2007; Singh et al., 2004c; Singh et al., 2001). Surface 
modifications have been achieved with anionic electrolytes such as sodium 
dioctylsulfosuccinate (Singh et al., 2004a; Singh et al., 2004b) and cationic electrolytes 
such as chitosan, poly(ethylene imine), or protamine (Fischer et al., 2006; Fischer et al., 
2007; Singh et al., 2004c; Singh et al., 2001). Protamine belongs to a group of low 
molecular weight (MW: 4000-4250 Da), arginine-rich, basic proteins, which condense 
DNA in the nucleus and are involved in spermatogenesis (Balhorn, 2007). Protamine is an 
FDA-approved compound, which has found applications in, e.g., stabilizing DNA 
(Elizabeth Collins, 2007), insulin complexation and formulation, and in reverting the 
anticoagulant effect of heparin (Brange and Langkjaer, 1992; Brange and Langkjaer, 1997; 
Byun Y, 2000). Protamine has been combined with PLGA microparticles for their use in 
mice (Dunne et al., 2003; Martinez Gomez et al., 2007) and used as a coating agent to bind 
nucleic acid on the surface of controlled-release particles (Csaba, 2007).  
The aim of this study was to evaluate the properties of protamine-coated PLGA 
microparticles with regard to particle uptake, antigen presentation, and the induction of T-
cell and antibody responses in mice.  
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MATERIALS AND METHODS 
Materials 
Purified phospholipase A2 (PLA2) from bee venom and chicken egg albumin (OVA; 
grade V) were purchased from Sigma-Aldrich (Buchs, Switzerland), and soy bean lecithin 
(Epikuron 200) from Degussa (Hamburg, Germany). Phosphorothioate-modified CpG 
oligodeoxynucleotide 1668pt (5’-TCC-ATG-ACG-TTC-CCT-GAC-GTT-3’) was 
synthesized by Microsynth (Balgach, Switzerland). The 35 kDa poly(lactide-co-glycolide) 
(PLGA 50:50) with uncapped end-groups (Resomer RG503H) was from Boehringer-
Ingelheim (Ingelheim, Germany). Protamine sulphate from salmon, poly(vinyl alcohol) 
(PVA; Mowiol 4-88) and dichloromethane (DCM) were from Fluka (Buchs, Switzerland). 
The GFP plasmid (pmaxFP-Green-C) was provided by Amaxa (Cologne, Germany). 
Mice 
BALB/c, CBA/J and C57BL/6 mice were purchased from Harlan (Horst, the 
Netherlands) and used at 6-10 weeks of age. DO11.10 mice were generously provided by 
Martin F. Bachmann (Cytos Biotechnology, Switzerland) and are transgenic for the T-cell 
receptor recognizing the OVA323-339 epitope on a 2Hd MHC-class II context in a BALB/c 
background (Murphy et al., 1990). OT-II mice were generously provided by Tobias Suter 
(University of Zurich, Switzerland). Also these mice are transgenic for the T-cell receptor 
recognizing the OVA323-339 epitope but on a C57BL/6 (2Hb MHC II) background (Barnden 
et al., 1998). All mice experiments were approved and performed according to guidelines 
formulated by the Veterinary authorities of the canton of Zurich, and the mice were kept in 
a specific pathogen free (SPF) environment.  
Microparticle preparation 
PLGA microparticles were made by microextrusion-based w/o/w-solvent extraction 
using a static multilamination type micromixer (Institut für Mikrotechnik Mainz, Mainz, 
Germany), as previously described (Freitas et al., 2003), with slight modifications. Three 
groups of formulations with different loads were prepared, with and without a protamine 
coating on the surface (Table 1). In the first group of microparticles, PLA2 was 
encapsulated for later evaluation of humoral responses. Briefly, 2 mg of PLA2 were 
dissolved in 100 µl water and emulsified on ice (ultrasonication with a probe for 10 
seconds; 40% amplitude, UP200H, Hielscher Ultrasonics, Teltow, Germany) into 0.6 g of 
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PLGA dissolved in DCM (5%, w/w). This w/o-emulsion was extruded through the 
micromixer along with a 0.5% (w/w) PVA aqueous solution as extraction phase; the 
resulting suspension of microparticles was collected using the same aqueous solution of 
0.5% (w/w) PVA for further solvent extraction and evaporation. To obtain positively 
charged microparticle coating, 0.5% (w/w) protamine solution was used as first extraction 
phase and water as final collection fluid. The particles were gently stirred using a magnetic 
rod and kept under laminar air-flow for 30 min for further solvent removal and hardening. 
Finally, the microparticles were collected on a mixed cellulose ester membrane filter with a 
pore size of 0.8 µm (Whatman, Dassel, Germany) and dried at 20 mbar and at room 
temperature for 24 h.  
The second group of microparticles, with and without protamine coating, contained 
pGFP. They were prepared for analyzing particle uptake by cells and particle-mediated cell 
transfection. Briefly, pGFP (0.7 mg) was dissolved in Tris-EDTA (TE) buffer (0.2 ml) and 
emulsified in PLGA (0.2 g) dissolved in DCM (5%, w/w). The subsequent steps for 
microparticle formation were as described above. 
The third group of microparticles, with and without protamine coating, was loaded with 
OVA for subsequently analyses of T-cell responses. Briefly, OVA (50 mg) was dissolved 
in PBS (0.8 ml), emulsified in PLGA (1 g) dissolved in DCM (5%, w/w), and further 
processed as described above. 
Particle size and zeta potential measurements 
Microparticle size distributions were determined by laser light diffraction (Mastersizer 
X, Malvern Instruments Malvern, United Kingdom) with a suspension of approx. 1 mg of 
dry microparticles in distilled water. A volume-weighted size distribution with 10%, 50% 
and 90% undersize diameters (D10, D50 and D90) was determined. The surface charge of the 
microparticles was determined by zeta potential measurement (Zetasizer 3000 HAS, 
Malvern Instruments). Dry microparticles (0.2 mg) were suspended in 1 mM KCl (2 ml; 
pH = 7.6), and the mean zeta potential value was calculated from two samples per batch 
and triplicate analysis per sample.  
Internalization of pGFP-loaded PLGA microparticles (MP) by HEK cells 
The role of the protamine in the particle uptake by cells was studied by measuring the 
transfection of Human Embryonic Kidney (HEK) cells upon incubation with microparticles 
containing the plasmid pGFP, taking use of the fact that positive transfection would 
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necessarily imply uptake of the plasmid containing particle by the cell; preliminary studies 
with FITC or coumarin-loaded particles were also done, but these did not allow to clearly 
distinguish between internalized particles and particles attached to the cell surface. Cells 
were seeded in 24-well plates pre-coated with poly-D-lysine at a density of 3x105 per well. 
One day after seeding, 50, 100 or 200 µg of pGFP-MP or pGFP-MP/protamine were added 
to the cells in duplicates; after incubation for 4 hours and various subsequent washes, the 
cells were incubated with fresh complete medium. The transfection of cells was monitored 
for two further weeks using a Zeiss Axiovert fluorescence microscope (Carl Zeiss, Jena, 
Germany). The average number of transfected (green) cells in 10 randomly selected bright 
light fields was counted. 
In vitro analysis of T–cell stimulation 
Murine dendritic cells were isolated from BALB/c bone-marrow and grown in 10 cm 
Petri dishes at a density of 1×106 cell/ml in 10 ml RPMI-1640 complete media containing 
20 ng/ml of granulocyte macrophage colony stimulating factor (GM-CSF) and 10 ng/ml of 
IL-4 (Immunotools, Friesoythe, Germany). After 2 and 4 days, the culture medium was 
replaced by fresh medium containing GM-CSF and IL-4. After 6 days, immature DCs were 
collected and seeded at 1×105 cells per well in a 96-well plate and then pulsed for 3 h at 
37°C and 5% CO2 with escalating amounts of OVA-containing microparticles, empty 
microparticles (1 or 100 µg) or aqueous OVA (10 or 100 µg/ml). After three washing steps, 
the cells were co-cultured with splenocytes (1x105 cells/well) from DO11.10 mice. After 
20 h, aliquots of the supernatant were taken for IL-2 determination. Lymphocyte 
proliferation was measured after 48 h by [3H] thymidine (1 µCi/well) incorporation during 
the last 16 h of culture using a 1450-MicroBeta TriLux liquid scintillation counter (Wallac, 
Finnland). 
Immunization of mice 
To evaluate the potential of the microparticles to stimulate T-cell responses in vivo, 6-
10 week old female OT-II mice were used. The mice were injected with 1 mg of OVA-MP 
or similar particles coated with protamine (OVA-MP/protamine); for injection, the 
microparticles were suspended in 1% aqueous lecithin solution. Blood was withdrawn at 
different time points (7, 14 and 21 days), and the lymphocytes analyzed by flow cytometry 
for IFN-γ producing cells. 
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For the study of antibody responses, PLA2-containing microparticle formulations were 
tested in 6-10 weeks old female CBA/J mice. The formulations PLA2-MP or PLA2-
MP/protamine were suspended in 1% aqueous lecithin solution prior to subcutaneous 
injection of a particle dose equivalent to 1 µg of entrapped PLA2; 1.2 - 1.3 mg of 
microparticles were injected in a volume of 150 µl. The mice were boosted with the same 
preparation and dose after 28 days. Serum was prepared from blood taken on days 28, 55 
and 84 and frozen at -20°C until analyzed by ELISA. Additional two groups of mice were 
injected with the same two formulations PLA2-MP or PLA2-MP/protamine after addition 
of 3.1 nmole CpG. 
Flow cytometry 
Intracellular IFN-γ was assessed in blood of the OT-II mice injected with 1 mg of 
OVA-MP or OVA-MP/protamine. After lysis of the erythrocytes with hypotonic Red 
Blood Cell Lysis Buffer (Sigma-Aldrich), splenocytes were stimulated in vitro with soluble 
OVA (10 µg/ml) and brefeldin A (10 µg/ml) (Sigma-Aldrich) for 3 h at 37 °C and 5% CO2. 
For FACS staining, the cells were washed several times, incubated with anti-CD16/CD32 
for Fc-receptor blocking (5 min), and stained with anti-CD44-FITC and anti-CD4-APC 
antibodies for 30 min. Cells were then fixed with 1% paraformaldehyde for 10 min and 
subsequently stained with anti-IFN-γ-PE in PBS/0.5% saponine for 30 min. All stainings 
were done in PBS/2% FCS at 4°C, unless specified otherwise, and all antibodies were 
purchased from BD Pharmingen (San Diego, CA, USA). Samples were measured on a 
FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, USA), and data was analyzed 
using FlowJo software (Ashland, OR, USA) 
Antibody determination by enzyme-linked immunosorbent assay (ELISA) 
For detection of PLA2 antibodies, microtitre 96-well plates (Nunc Maxisorb, 
Wiesbaden, Germany) were coated with 5 µg/ml PLA2 in carbonate buffer at 4 °C 
overnight. The plates were blocked with 2.5% skinned dry milk in phosphate-buffered 
saline containing 0.05% Tween 20 (Serva, Heidelberg, Germany) (PBSTM) for 1 h. Then, 
serial dilutions of individual mice sera in PBSTM were incubated in the plates for 2 h. 
Next, the plates were incubated with 1 µg/ml biotinylated goat anti-mouse IgG1 or IgG2a 
(BD Bioscience Pharmingen) in PBSTM for 2 h. Subsequently, plates were incubated with 
a 1:1000 dilution of streptavidin-conjugated horse-radish peroxidase (BD Pharmingen) for 
1 h and developed with the enzyme substrate 2,2’-azino-bis(3-ethylbenzothiazoline-6-
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sulphonic acid) diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogenphosphate. 
The endpoint optical density was measured at 405 nm after 20 min incubation using a 
microplate reader Model 550 (BioRad, Hercules, CA, USA). All steps were intercepted by 
washings with PBST. 
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RESULTS 
Microparticle characterization 
Three different groups of microparticles, all with and without protamine coating, were 
prepared (Table 1). The formulations with encapsulated pGFP, named pGFP-MP or pGFP-
MP/protamine, had a very similar size distribution. Fifty percent of the particles were 
smaller than 3.2 µm or 3.5 µm, respectively. For both OVA- and PLA2-containing 
formulations, the size of the protamine-coated particles was larger than that of the non-
coated particles. This was most evident for the OVA-containing microparticles, where 50% 
of the OVA-MP/protamine were smaller than 7.2 µm as compared to 3.2 µm for the non-
coated particles (Table 1). Independent of the encapsulated antigen, the zeta potential of the 
protamine-coated microparticles was, as expected, positive (+11 to +65 mV), which is due 
to the polycationic charge of protamine; on the contrary, the non-coated particles had 
negative zeta potential (ranging from -11.8 to -2.4 mV). 
Table 1. Microparticle formulations. Characteristics and application of the different groups of formulations 
used in the current the study. 
 
Test 
formulation  
Zeta potential (mV) Size Distribution 
(µm) (D10/D50/D90) 
Study 
application 
pGFP-MP 
pGFP-MP/protamine 
-11.8 ±0.8 
  64.8 ± 4.3 
1.6 / 3.2 / 5.2 
1.9 / 3.5 / 5.3 
Particle 
uptake and 
transfection 
OVA-MP 
OVA-MP/protamine 
-11.6 ± 0.1 
 19.3 ± 0.6 
1.4 / 3.2 / 6.4 
2.3 / 7.2 / 20.9 
Antigen 
presentation 
and T cell 
responses 
PLA2-MP 
PLA2-MP/protamine 
 -2.4 ± 4.2 
10.5 ± 6.6 
1.2 / 4.4 / 24.9 
3.0 / 6.8 / 15.5 
B cell 
responses 
 
In vitro internalization of pGFP-loaded microparticles  
To examine the effect of the protamine coating on the internalization of the 
microparticles, HEK cells were incubated for 4 h with different amounts of pGFP-
containing particles, with or without protamine coating. Transfection of the cells was 
assessed as a measure for particle internalization by fluorescence microscopy. As 
illustrated in Figure 1A, only protamine-coated particles were able to transfect HEK cells. 
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The transfection was dose-dependent, as the efficacy increased with the amount of particles 
used in the culture (Fig. 1B). 
 
Figure 1. Internalization of microparticles containing pGFP by HEK cells. (A) Fluorescence microscopy 
pictures of cells incubated with 100 µg of protamine-coated or uncoated microparticles. Scale marker is 50 
µm. (B) Quantification of positive cells as assessed by counting the green cells in 10 bright randomly selected 
light fields per well, after 72 h of incubation with the microparticles. The data is representative of three 
similar experiments. 
 
In vitro proliferation of specific T cells 
To assess the role of the protamine coating in the presentation of encapsulated antigen, 
OVA-containing microparticles, with and without protamine coating, were incubated at 
escalating amounts with bone-marrow derived DCs from BALB/c mice. The pulsed DCs 
were then co-cultured with splenocytes derived from transgenic DO11.10 mice. After 20 
hours, the secretion of IL-2 in the supernatant was measured by ELISA and after 48 hours 
proliferation was determined by measuring the [3H] thymidine incorporation. Figure 2A 
reveals that the protamine coating enhanced the IL-2 secretion in a dose-dependent manner 
and with a 10-fold higher sensitivity than the uncoated particles. Correspondingly, the 
protamine coated particles also showed a 10-fold increased capacity to stimulate the 
proliferation of antigen-specific T cells (Fig. 2B). The highest concentration of protamine-
coated particles stimulated the secretion of IFN-γ (data not shown). This effect of 
protamine was also observed when compared to stimulation of splenocytes using DCs 
pulsed with soluble OVA. Cells stimulated with 100 µg/ml or 10 µg/ml OVA solution 
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produced very low or even undetectable levels of IL-2 (Fig. 2A), and moderate and 
concentration-dependent T-cell proliferation (Fig. 2B). Unloaded microparticles, with or 
without the protamine coating, did neither stimulate IL-2 production nor lymphocyte 
proliferation (data not shown). 
 
Figure 2. In vitro stimulation of OVA specific T cells. Bone marrow derived DCs from BALB/c mice were 
pulsed for 3 h with different amounts of OVA-loaded microparticles and then incubated with splenocytes 
from DO11.10 mice in tripiclates. After 20 h, IL-2 was measured in the supernatants (A), and after 48 h, cell 
proliferation was determined by [3H] thymidine incorporation (B). Data was analyzed by Two Way ANOVA 
with Bonferroni post test (*** p<0.0001; ** p<0.01). 
 
Stimulation of T-cell responses in mice 
The capacity of microparticles to enhance the induction of T-cell responses in vivo was 
evaluated in transgenic OT-II mice. Animals were injected with 1 mg of either uncoated or 
protamine-coated microparticles containing OVA protein, OVA-MP or OVA-
MP/protamine, and T-cell responses were assessed by measuring the activated CD4 T cells 
producing IFN-γ after 7, 14 and 21 days. Mice injected with OVA-MP/protamine induced 
higher frequencies of IFN-γ producing CD4 T cells at all time points as compared to mice 
that received OVA-MP (Fig. 3).  
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Figure 3. In vivo induction of T cell responses. OT-II mice were immunized with microparticles containing 
OVA (n=5), and the percentage of IFN-γ producing CD4 T cells in peripheral blood was measured by flow 
cytometry after 7 (A), 14 (B) and 21 (C) days. Untreated mice were used as negative controls. Data was 
analyzed by One Way ANOVA with Tukey’s Multiple Comparison Test (*** p<0.0001; ** p<0.01; * 
p<0.05). 
 
As early as day 7 (Fig. 3A) the protamine-coated microparticles induced significant 
levels of IFN-γ producing cells, in contrast to the uncoated microparticles that needed an 
additional week to raise a moderate response. At day 14, less than 2% of the cells from the 
mice immunized with the uncoated particles were IFN-γ producing CD4 T cells as 
compared to 3% achieved with the protamine-coated particles (Fig. 3B). Maximal response 
was attained with both formulations at day 14 after the injection (Fig. 3B). Untreated mice 
were used to determine the background levels of IFN-γ in the OT-II mice. 
Stimulation of B-cell responses in mice 
To evaluate the effect of the protamine coating on the stimulation of B-cell responses, 
CBA/J mice were immunized with microparticles containing the major bee venom allergen 
PLA2. The antibody responses were determined at 28, 55 and 84 days after the first 
injection. After the first injection, the protamine-coated particles induced a weak PLA2-
specific IgG1 response, while the uncoated particles failed to do so, as measured 28 days 
after the priming (Fig. 4A). When a second dose was administered at day 28, the IgG1 
response was strongly boosted by the protamine-coated particles, but not by the uncoated 
particles. The IgG1 levels remained high for at least 84 days. Two injections were required 
to induce a detectable IgG2a response; and again, the response, although weak, was 
stronger in mice immunized with the protamine-coated particles (Fig. 4C). 
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Figure 4. In vivo stimulation of humoral responses. CBA/J mice were immunized at day 0 and boosted at day 
28 with PLA2-containing microparticles, with or without protamine coating, (A,C) and admixed with CpG 
(B,D) (n=4). Blood was collected at days 28, 55 and 84, and analyzed by ELISA for anti- PLA2 IgG1 (A,B) 
and IgG2a (C, D) antibodies. The absorbance at 1/800 serum dilution was chosen for comparing the groups at 
each time point. Data was analyzed by One Way ANOVA with Tukey’s Multiple Comparison Test (*** 
p<0.0001; ** p<0.01; * p<0.05). 
 
For assessing whether the observed benefit of the protamine coating persisted in the 
presence of an additional adjuvant, the two PLA2-loaded microparticle formulations were 
admixed with immune stimulatory CpG prior to injection. The previously observed Th2-
biased response was shifted in the presence of CpG towards Th1, with both PLA2-MP and 
PLA2-MP/protamine (Fig. 4D). The IgG1 levels increased for both formulations, but the 
protamine-coated particles again stimulated stronger responses than the uncoated particles 
(Fig. 4B). 
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DISCUSSION 
Microparticles of PLGA have been widely studied for their use as drug and antigen 
delivery systems (Johansen et al., 2000; Mundargi et al., 2007; Storni et al., 2005). These 
particulate systems are able to deliver drugs or antigens such as DNA, proteins, and 
peptides over prolonged periods of time, and to induce strong immune responses against 
encapsulated antigens (Espuelas S., 2005), which makes them attractive candidates for 
vaccine development. 
Stability issues with encapsulated biologicals have led to an alternative method for 
associating antigens and DNA with PLGA microparticles, namely by adsorbing the 
bioactive materials onto the surface of anionic or cationic particles (Singh et al., 2004b; 
Singh et al., 2004c). Yet, not many studies have addressed the question if and to what 
extent the modified particle surface itself influences the induction of immune responses in 
vivo. In the current study, we investigated the immunological effects of coating PLGA 
microparticles with the cationic electrolyte protamine for stimulation of humoral and 
cellular immune responses to various antigens.  
In mice immunized with microparticles containing the bee venom major allergen 
PLA2, we found that protamine-coated particles were more immunogenic than uncoated 
particles and enhanced the induction of long-lasting IgG1 antibody responses. In mice, the 
IgG1 subclass is associated with Th2 responses and is important to fight extracellular 
pathogens. In contrast, IgG2a is associated with Th1 and cytotoxic T-cell responses that are 
essential for inflammatory processes and in controlling intracellular pathogens. Although 
the protamine-coated particles also stimulated stronger IgG2a antibody responses than the 
uncoated microparticles, the overall IgG2a/Th1 response was weak, but could be strongly 
improved by admixing immunostimulatory CpG. In the presence of CpG, protamine-coated 
microparticles promoted again a stronger immune response than the uncoated particles. 
This capacity of polarizing the immune responses towards Th1 or Th2, as a function of the 
co-formulation with immune-response modifiers, may be exploited for different 
vaccination strategies, depending on the desired outcome. 
The improved humoral immune responses after immunization with the protamine-
coated microparticles prompted us to study whether protamine also affected the stimulation 
of T cells. Indeed, enhanced T-cell responses to ovalbumin were observed in mice after 
using OVA-containing particles coated with protamine. Although, differences were not as 
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striking as for the humoral responses, there was a significant increase in the percentage of 
IFN-γ producing CD4 T cells at all time points examined when compared to the uncoated 
particles. The enhanced immunogenicity of the protamine-coated particles was mediated 
through their preferential interaction with professional antigen-presenting cells. Bone-
marrow derived DCs pulsed with protamine-coated microparticles stimulated antigen-
specific T cells in vitro more efficient than did DCs pulsed with uncoated microparticles. 
One potential reason for the difference between protamine-coated and protamine-free 
particles with respect to their in interaction with APCs could have been differences in 
particle size distribution of the formulations. In this study, the size distribution of the 
uncoated OVA-containing microparticles was ideal for uptake, since 90% of the particles 
were smaller than 6.4 µm, and only particles smaller than 5-10 µm have been shown to be 
efficiently taken up by antigen presenting cells (Men et al., 1999; Peyre et al., 2004b). 
However, as the protamine-coated microparticles had a broader size distribution than the 
uncoated ones, with only 50% of the particles being smaller than 7.2 µm, the size cannot 
explain the increased in vitro and in vivo immune responses of the protamine-coated 
particles.  
Besides particle size, particle surface charge may also influence the interaction with 
APCs. Positively charged particles are more likely to bind to the negatively charged cell 
surfaces, and thereby facilitate uptake and stimulation of immune responses. Indeed, 
cationic microparticles have been reported to enhance phagocytosis by DCs and 
macrophages in comparison with unmodified particles (Thiele et al., 2003; Thiele et al., 
2001; Wischke et al., 2006). The mechanism suggested for the enhanced uptake in those 
studies is the electrostatic attraction between the positively charged microparticles and the 
negatively charged cell surface mediating binding and subsequent internalization. In 
addition to its positive charge at physiological pH, protamine specifically contains 
arginine-rich sequences, which share structural similarity with certain viral proteins such as 
the Tat from the Human Immunodeficiency Virus (HIV-1) or the VP22 from the Herpes 
Simplex Virus, both of which possess protein translocation activity (Futaki et al., 2001; 
Jarver and Langel, 2006; Schwarze et al., 2000). These sequences of basic amino acids 
mediate the penetration of viruses into cells in an energy-independent manner (Lundberg 
and Langel, 2003); thus, these so-called cell penetrating peptides or peptidic moieties 
appear to be particularly good candidates as transporters for drug delivery. While the cell 
penetrating property of Tat peptides have been extensively studied (Brooks et al., 2005; 
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Fittipaldi and Giacca, 2005; Torchilin, 2008), the potential of protamine to carry cargos 
across the cell membrane is less recognized. However, in 2005, two independent groups 
reported that protamine can act as an efficient membrane-translocating peptide both in vitro 
(Reynolds et al., 2005) and in vivo (Park et al., 2005; Reynolds et al., 2005). Park et al. 
showed that a protein toxin conjugated to protamine was able to translocate into cells in 
vitro, resulting in the inhibition of tumor growth in vivo. It was also reported that Tat-
carrying (Lewin et al., 2000) and protamine-carrying (Reynolds et al., 2005) iron 
nanoparticles were readily internalized by cells. Moreover, Tat-liposomes of 200 nm 
showed potential for intracellular gene delivery in vitro and in vivo (Torchilin and 
Levchenko, 2003; Torchilin et al., 2003). These experiments suggest that the improved 
immunological performance of protamine-coated antigen-containing PLGA microparticles 
was mediated by the cell-penetrating properties of the arginine-rich protamine. To confirm 
this hypothesis we tested the uptake and transfection of non-phagocytic HEK cells using 
microparticles that contained a plasmid coding for GFP with or without protamine coating. 
Indeed, protamine-coated particles were capable to transfect the HEK cells, whereas 
uncoated particles did not possess this capacity. The same was observed when testing the 
particles on non-phagocytic melanoma cells (data not shown). As the size distribution of 
the tested formulations was almost identical (±0.3 µm), the observed differences must be 
ascribed to protamine and its ability to translocate the microparticles intracellularly.  
Although, there is certain controversy in the literature concerning the translocation 
mechanisms of cell-penetrating peptides, recent data suggests more than one mechanism. 
Studies using Tat-nanoparticles or Tat-liposomes suggest that the translocation mechanism 
occurs via energy-dependent macropinocytosis (Gupta et al., 2005; Torchilin, 2008), 
whereas peptide-conjugated small molecules penetrate via electrostatic interactions and do 
not seem to depend on energy (Herce and Garcia, 2007). The exact mechanism of 
protamine-mediated penetration of microparticles into non-phagocytic cells remains to be 
clarified. 
Taken together, we have shown the increased immunogenicity of antigens encapsulated 
in protamine-coated PLGA microparticles as compared to uncoated particles and proposed 
a possible mechanism of action. Additional research to characterize protamine-coated 
particles is required to develop further a new technology combining the advantages of 
microparticles for prolonged antigen release and protamine for facilitating cell penetration 
of the delivery system. The potential applications of such an intracellular delivery system 
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technology may span the areas of vaccine development, cancer immunotherapy, and 
gene/protein delivery. 
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